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The toxicity of a mentholated version of the Tobacco Heating System (THS2.2M), a candidate modiﬁed
risk tobacco product (MRTP), was characterized in a 90-day OECD inhalation study. Differential gene and
protein expression analysis of nasal epithelium and lung tissue was also performed to record exposure
effects at the molecular level.
Rats were exposed to ﬁltered air (sham), to THS2.2M (at 15, 23 and 50 mg nicotine/l), to two
mentholated reference cigarettes (MRC) (at 23 mg nicotine/l), or to the 3R4F reference cigarette (at 23 mg
nicotine/l). MRCs were designed to meet 3R4F speciﬁcations.
Test atmosphere analyses demonstrated that aldehydes were reduced by 75%e90% and carbon
monoxide by 98% in THS2.2M aerosol compared with MRC smoke; aerosol uptake was conﬁrmed by
carboxyhemoglobin and menthol concentrations in blood, and by the quantities of urinary nicotine
metabolites.
Systemic toxicity and alterations in the respiratory tract were signiﬁcantly lower in THS2.2M-exposed
rats compared with MRC and 3R4F. Pulmonary inﬂammation and the magnitude of the changes in gene
and protein expression were also dramatically lower after THS2.2M exposure compared with MRCs and
3R4F.
No menthol-related effects were observed after MRC mainstream smoke-exposure compared with
3R4F.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The U.S. Family Smoking Prevention and Tobacco Control Act
(FSPTCA) deﬁnes a Modiﬁed Risk Tobacco Product (MRTP) as “any
tobacco product that is sold or distributed for use to reduce harm or(P. Vanscheeuwijck).
anies
Inc. This is an open access article uthe risk of tobacco related disease associated with commercially
marketed tobacco products” (Family Smoking Prevention and
Tobacco Control Act). This publication is part of a series of nine
publications describing the nonclinical and part of the clinical
assessment of a candidate MRTP, THS2.2 regular and a mentholated
version (THS2.2M). The series of publications provides part of the
overall scientiﬁc program to assess the potential for THS2.2 to be a
reduced risk product. The ﬁrst publication in this series describes
THS2.2 and the assessment program for MRTPs (Smith et al., 2016).
This is followed by six publications, including this one, that
describe the nonclinical assessment of THS2.2 regular and THS2.2Mnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
THS2.2 Tobacco Heating System 2.2
HPHCs harmful and potentially harmful constituents
MRTP modiﬁed risk tobacco product
THS2.2Mmentholated version of the Tobacco Heating System
MRC mentholated reference cigarettes
MA mainstream aerosol
MS mainstream smoke
OECD Organization for Economic Cooperation and
Development
GLP Good Laboratory Practice
RNE respiratory nasal epithelium
EHC Electrically Heated Cigarette
TPM total particulate matter
CO carbon monoxide
AAALAC American Association for the Accreditation of
Laboratory Animal Care
AVA Agri-Food & Veterinary Authority of Singapore
NACLAR National Advisory Committee for Laboratory Animal
Research
BALF bronchoalveolar lavage ﬂuid
PDSP Programmable Dual-port Syringe Pump
GC gas chromatograph
COHb carboxyhemoglobin
PBS phosphate-buffered saline
BSA bovine serum albumin
EGAFS ethanol glycerol acetic acid formaldehyde saline
H&E hematoxylin and eosin
FC fold-changes
MMAD mass median aerodynamic diameter
GSD geometrical standard deviation
NNIC nornicotine
NCOT norcotinine
30HOCOT 30-hydroxycotinine
COT cotinine
NN’O nicotine-N0-oxide
HPMA 3-hydroxypropylmercapturic acid
NNAL 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
SPMA S-phenylmercapturic acid
CEMA 2-cyanoethylmercapturic acid
NNK 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
M-I p-menthane-3,8-diol
BW Body weight
CCL Chemokine (C-C motif) ligand
M-CSF-1 macrophage colony-stimulating factor
MMP9 metalloproteinase 9
DEGs differentially expressed genes
DEPs differentially expressed proteins
HED Human Equivalent Doses
LOD Limit of Detection
LOQ Limit of Quantiﬁcation
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Schaller et al., 2016a (in this issue); Schaller et al., 2016b (in this
issue); Sewer et al., 2016 (in this issue); Wong et al., 2016 (in this
issue)). The eighth publication in the series describes a clinical
study to assess whether the reduced formation of Harmful and
Potentially Harmful Constituents (HPHC) for THS2.2 regular also
leads to reduced exposure to HPHCs when the product is used in a
clinical setting (Haziza et al., 2016 (in this issue)). A ﬁnal publication
utilizes data gathered from the reduced exposure clinical study on
THS2.2 regular to determine if a systems pharmacology approach
can identify exposure response markers in peripheral blood of
smokers switching to THS2.2 (Martin et al., 2016 (in this issue)).
Here we report on the toxicological data generated in a 90-day
inhalation study on rats using THS2.2M, the mentholated version
of THS2.2, and compare it with mentholated reference cigarettes
(MRC). The MRCs were designed and manufactured by Philip
Morris Products S.A. to be similar to the 3R4F reference cigarette
from the University of Kentucky (http://www.ca.uky.edu/refcig/) in
terms of general smoke parameters, but with menthol added to
match menthol levels achieved in the aerosol from THS2.2M. The
smoke chemistry analysis and in vitro toxicity of TH2.2M is sum-
marized in Schaller et al. (2016a (in this issue)) further details on
the MRC are described here.
Menthol is commonly used as a ﬂavor in cigarettes. Although
the toxicological properties of menthol are well described (World
Health and Expert Committee on Food, 2015), the clinical effects
of applying menthol to cigarettes are less well understood. It has
been suggested that menthol in cigarettes may increase smoke
exposure by affecting smoking behavior and topography (as
reviewed by Wickham, (2015)), increasing the cigarettes' nicotine
impact, or increasing exposure to toxic smoke constituents. On the
other hand, results from clinical studies showed that smokers of
menthol and nonmenthol cigarettes exhibit similar levels of bio-
markers of smoke exposure (urinary nicotine and metabolites aswell as NNAL, and carboxyhemoglobin) (Heck, 2009). Another
study, from the Center for Tobacco Products at the Food and Drug
Administration (Rostron, 2013) showed that upon analyzing uri-
nary NNAL concentrations in a large group of U.S. smokers, NNAL
concentrations were lower among menthol smokers compared
with nonmenthol smokers among smokers overall and White
smokers. Finally, a small study assessing the impact of menthol on
smoking behaviors, biomarkers of exposure and subjective re-
sponses concluded a minimal impact for menthol (Strasser et al.,
2013). This issue is subject of ongoing debate and out of scope for
the work presented, focusing on the toxicological properties of
mentholated THS2.2, compared with those elicited by mentholated
reference cigarettes. However, exposure levels have been assessed
through the quantiﬁcation of biomarkers of exposure in the present
study, comparing these biomarkers in rats exposed to smoke from
mentholated reference cigarettes and the nonmentholated refer-
ence 3R4F.
The main objective of the current study was to characterize the
toxicological effects of MA from THS2.2M, including pulmonary
inﬂammation, and to compare themwith those elicited byMS from
MRC in a 90-day sub-chronic rat inhalation study, to assess whether
THS2.2M causes additional toxicity compared with the smoke from
mentholated cigarettes. Additional endpoints, such as differential
gene and protein expression, were added to better describe po-
tential changes on the molecular level.
In the current study, the reference cigarette 3R4F was included
as an internal reference. Results from MRCs and 3R4F were
compared to determine any signiﬁcant alterations of smoke-related
biological effects resulting from the addition of menthol to
cigarettes.
Smoke from lit-end cigarettes contains more than 8000 chem-
ical compounds (Rodgman and Perfetti, 2013), whereas the heat-
not-burn tobacco product design lowers the extent of pyrolysis
and quantity of combustion products (Coggins et al., 1989; Werley
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bacco products have been previously reported (Moennikes et al.,
2008; Schorp et al., 2012; Werley et al., 2008), and the THS2.2M
tested in this study is an evolution of these products. THS2.2M
tobacco sticks are heated in a stick holder in an electronic device
(Smith et al., 2016 (in this issue)). The aerosol generated contains
mainly water, glycerin, nicotine, and tobacco ﬂavors, while it has
markedly lower quantities of harmful and potentially harmful
chemical constituents because of the absence of combustion of
tobacco, compared with 3R4F (Schaller et al., 2016a (in this issue)).
The 90-day rat repeated exposure nose-only inhalation toxicity
study was performed following the Organization for Economic
Cooperation and Development (OECD) guideline 413 (OECD, 2009),
supplemented with additional endpoints and the following de-
viations for the reference cigarettes for practical limitations: (1)
Since no mentholated reference cigarettes were available from the
University of Kentucky, MRCs were designed and manufactured by
Philip Morris International to meet the tar, nicotine, carbon mon-
oxide (CO), and cigarette diameter speciﬁcations of 3R4F. (2) Rats
were exposed to three concentrations (with nicotine as dosing
parameter) of aerosol from THS2.2M and to MS from only two MRC
controls with menthol concentration in the test atmosphere to
matchmenthol levels similar to those in THS2.2M. (3) MS from both
MRCs had the same nicotine concentration in the test atmosphere
to match the medium nicotine concentration of the MA from
THS2.2M. Higher nicotine test atmosphere concentrations for the
MRCs were not achievable because of the toxicity related to CO
levels in MS.
Since previous studies with candidate modiﬁed risk tobacco
products (MRTP) showed reduced toxicological effects compared
with 3R4F exposure on OECD endpoints (Kogel et al., 2014; Patskan
and Reininghaus, 2003; Terpstra et al., 2003; Werley et al., 2008),
systems toxicological endpoints were included in this study to add
a level of granularity in the description of the changes that may be
induced by MA from THS2.2M. Gene and protein expression data
were generated from the respiratory tract tissues, i.e. nasal
epithelium and lung tissue, that were expected to be affected byMS
and MA exposure and showed histological changes (Moennikes
et al., 2008; Terpstra et al., 2003; Vanscheeuwijck et al., 2002).
While emphasis is placed in this manuscript on the global molec-
ular response proﬁles measured using omics technologies, more
extensive analyses of these endpoints are provided in our accom-
panying manuscript by Kogel et al. (Kogel et al., 2016 (in this issue))
Detailed THS2.2M smoke chemistry and in vitro assay data on
mutagenicity/genotoxicity and cytotoxicity are presented in
Schaller et al. (2016a (in this issue)).
2. Materials and Methods
2.1. Experimental design
This 90-day inhalation study was designed to characterize po-
tential adverse toxicological effects of exposure to mainstream
aerosol (MA) from the mentholated MRTP THS2.2 and to compare
them with those elicited by mainstream smoke (MS) from
mentholated reference cigarettes (MRC) in SpragueeDawley rats
following the OECD Test Guideline 413 (OECD, 2009). The Test
Guideline has been designed to fully characterize test article
toxicity by the inhalation route for a subchronic duration (90 days),
and to provide robust data for quantitative inhalation risk assess-
ments. The study was conducted according to the OECD Principles
on Good Laboratory Practice (GLP) (as revised in 1997). Exposure
concentrations were based on the nicotine content in the test at-
mospheres, which was 23 mg/l for MRCs and 15, 23, and 50 mg/l for
THS2.2M. The reference cigarette 3R4F (exposure concentration of23 mg nicotine/l) was used as an internal reference in this study.
To assess the effects of THS2.2M in terms of additional toxicity
that would not be seen in the endpoints prescribed by OECD TG
413, gene and protein expression investigations were performed on
the molecular level. As this analysis is performed on rats exposed
according to the same protocol as the rats used for the determi-
nation of the OECD-recommended endpoints, and because expo-
sure was performed concomitantly, this additional analysis is
therefore referred as the “OECD plus” part. Gene and protein
expression data were generated from tissues at anatomical sites
where histological changes are expected (Terpstra et al., 2003;
Vanscheeuwijck et al., 2002), and from which sufﬁcient tissue can
be obtained for gene expression analysis, i.e. the respiratory nasal
epithelium (RNE) and lung parenchyma tissues.
2.2. THS2.2 tobacco sticks and reference cigarettes
THS2.2M blend FR1/Menthol containing different elements
(tobacco plug, transfer section, and mouth piece) assembled with
an over-wrapping of cigarette paper with a menthol yield in smoke
condensate of 2.09 mg/cig when smoked according to ISO 3308
(3308:2012, 2012), were provided by Philip Morris Products S.A.,
Neucha^tel, Switzerland. THS2.2 is an evolution of the Electrically
Heated Cigarette (EHC) and heats the tobacco in tobacco sticks, thus
lowering the quantity of pyrolysis and combustion products
(Schaller et al., 2016a (in this issue)). THS2.2M contains natural
menthol applied to a cellulose acetate yarn included in the
polymer-ﬁlm ﬁlter and to the inner liner paper included in the
tobacco stick pack. Natural menthol contains mainly L-menthol.
The device includes a battery, controlling electronics, a heating
element, and the stick extractor, and was provided by Philip Morris
Products S.A. At the operating temperature of THS2.2M, pyrolysis of
menthol can be excluded (Jenkins et al., 1970).
Two MRC versions were designed to match the nicotine, total
particulate matter (TPM), and carbon monoxide (CO) levels of the
3R4F reference cigarette with a menthol yield in smoke condensate
of 2.04 mg/cig (MRC(LM)) and 2.58 mg/cig (MRC(HM)) when
smoked according to the ISO 3308 (3308:2012, 2012) standard.
These menthol levels were chosen to be in the range of those in the
aerosol from THS2.2M. MRC have been manufactured by Philip
Morris Products S.A., Neuchatel, Switzerland for the purpose of the
present study. Smoke tar levels were 9.9 and 10.5 mg/cig, nicotine
0.64 and 0.64 mg/cig and CO 11.4 and 11.3 mg/cig for MRC(LM) and
MRC(HM) respectively. For comparison, in smoke from 3R4F tar is
9.4 mg/cig, nicotine 0.7 mg/cig and CO 12.0 mg/cig. ForMRC(LM), L-
menthol (CAS 2216-51-5) was added to 11.1 mg/cig (9.0 mg/cig in
the ﬁlter, 2.1 mg/cig pack inner liner), for MRC(HM) 18.4 mg/cig
(9.0 mg/cig in the ﬁlter, 3.9 mg/cig pack inner liner, 5.5 mg/cig cut
ﬁller or tobacco rod). The L-menthol used had a purity >99%.
The 3R4F reference research cigarettes were purchased from the
University of Kentucky (http://www2.ca.uky.edu/refcig/).
2.3. Animals and treatment
All procedures involving animals were performed in an AAALAC
(American Association for the Accreditation of Laboratory Animal
Care) accredited, AVA (Agri-Food & Veterinary Authority of
Singapore) licensed facility with approval from an Institutional
Animal Care and Use Committee, and performed in compliance
with guidelines set by the National Advisory Committee for Labo-
ratory Animal Research (NACLAR). All procedures were conducted
in compliance with GLP, with the exception of bronchoalveolar
lavage ﬂuid (BALF) cytokine analysis and transcriptomics and pro-
teomics investigations.
Outbred male and female SpragueeDawley rats [Crl:CD(SD)],
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Charles River, USA (breeding area Raleigh R04, Raleigh, NC, USA).
Upon arrival, the health status of a group of six animals per sex was
veriﬁed by histopathological examination and serological screening
(as described in Vanscheeuwijck et al. (2002)), and by examining
the health report from the sourced breeding area. The rats were
kept and exposed in an animal laboratory with restricted access
under controlled conditions of good hygiene. The laboratory air was
ﬁltered fresh air, and positive pressure was maintained inside the
laboratory. The room temperature was maintained at 22 ± 3 C, and
the relative humidity at 54 ± 4%. The light/dark cycle was 12 h/12 h,
the light period starting at 7a.m. Identiﬁcation, housing, feeding,
and watering were performed as described previously
(Vanscheeuwijck et al., 2002).
For the OECD and OECD plus part of the study, 102 male and 102
nulliparous and non-pregnant female rats were individually iden-
tiﬁed by means of subcutaneous transponders, and were random-
ized to the different treatment groups stratiﬁed by sex and body
weight the day before the ﬁrst exposure. The relative standard
deviation of body weight for each group and sex was smaller than
10%. For the OECD part, 10 rats per sex were allocated to either the
ﬁltered, conditioned air group (sham) or 5 aerosol-exposure
groups: MRC(LM) 23 mg nicotine/l, MRC(HM) 23 mg nicotine/l, low
THS2.2M (THS2.2M Low, 15 mg nicotine/l), medium THS2.2M
(THS2.2M Medium, 23 mg nicotine/l), or high THS2.2M (THS2.2M
High, 50 mg nicotine/l). In addition, 8 rats per sex from the sham,
3R4F, MRC(HM), and THS2.2M High groups were kept for a 42 day
recovery period. For the molecular endpoints (OECD plus part), 6
male and 6 female rats were allocated to each 90-day exposure
group, and 6 female rats to the recovery group. The rats from the
recovery groups and OECD plus groups were exposed concomi-
tantly and in the same exposure chambers as the rats from themain
study. The age of the rats at the start of the inhalation period was
8e10 weeks. The body weights were within 20% of the mean
weight for each sex (172 g for females and 190 g for males). In-life
observations were recorded.
2.4. Test atmosphere generation and exposure
Before test atmosphere generation, mentholated tobacco sticks
and MRCs were unpacked, placed in sealed boxes in order to
minimize menthol losses, and conditioned in sealable climate
chambers for 1e3 days prior to smoking, at a temperature of
22.5 ± 0.2 C and 58.6 ± 0.3% relative humidity. Test atmosphere
was generated in basic conformity with the Health Canada Intense
smoking protocol, i.e. puff duration, 2.0 s; puff volume, 55 ml; puff
frequency, 2/60 s (Burns et al., 2008; Health Canada, 1999), with
some minor deviations (e.g. smoking whole puffs instead of
rounding to the nearest tenth of a puff) necessary for technical
reasons.
MS from 3R4F and MRCs was generated on 30-port rotary
smoking machines (15 ports blocked) equipped with a Program-
mable Dual-port Syringe Pump (PDSP) with active side stream
exhaust (type PMRL-G, SM2000) (Kogel et al., 2014). Smoking
machines were designed by Philip Morris Products S.A. and man-
ufactured by Burghart Messtechnik, Weidel, Germany (http://
www.burghart-mt.de/). MA from THS2.2M was generated using
30-port carousel smokingmachines with a smoking device docking
station equipped with stick holders and a PDSP. The docking station
served as an interface to ensure synchronization between the
cigarette holder and the smoking machine. The THS smoking ma-
chines also included a temperature-controlled insulation kit (tube
warming system) in the undiluted aerosol pathway, to reduce
aerosol condensation prior to dilution to the targeted aerosol
concentration.Test atmosphere was diluted with ﬁltered, conditioned air to
obtain the target nicotine concentrations (8, 15, or 23 mg nicotine/l).
The rats were nose-only exposed to the test atmosphere for 6 h/d,
5 d/week for a period of 90 days (13 weeks) using ﬂow pass inha-
lation chambers as previously described (Wong et al., 2016 (in this
issue)). A post-inhalation period of 42 days was included to
investigate reversibility, persistence, and delayed occurrence of
exposure effects. A 5-day dose-adaptation regimen was applied at
the start of the inhalation period. On study days 1 and 2, the rats
were exposed to one third of the target concentrations. On study
days 3 and 4, they were exposed to two thirds of the target smoke
concentrations. From day 5 onward, they were exposed to target
concentrations. The 90-day exposure period is deﬁned in OECD TG
413 (OECD, 2009).
The 3R4F reference cigarette was used as an internal reference
to classify the severity of effects of MRCs and to monitor consis-
tency with historical data of the laboratory.
2.5. Analytical characterization of the test atmospheres
To monitor the stability and reproducibility of test atmosphere
generation, nicotine, TPM, CO, and aldehydes (formaldehyde,
acetaldehyde, and acrolein) were determined at the breathing zone
of the rats, as well as the particle size distribution and the tem-
perature in the exposure chambers. Relative humidity was
measured in the sham exposure chamber only. All evaluations were
performed according to previously described analytical methods
(Haussmann et al., 1998; Stabbert et al., 2003).
For the determination of menthol in the diluted test atmo-
sphere, samples were collected using an ethanol-impregnated
diatomaceous earth column (EXtrelut® NT 3, Merck, USA). The
EXtrelut® NT 3 column was impregnated with 2 ml of analytical
grade ethanol (min. 99.8%) 15 min before sampling. Sample
collection was carried out for 30 min at a ﬂow of 0.7 l/min. After
sample collection, the column was sealed at both ends to prevent
evaporation of menthol during transfer to laboratory for analysis.
All collected samples were processed immediately by adding 250 ml
of a 4 mg/ml N-heptadecane standard in ethanol to each column
prior to elution with 25 ml of ethanol for a total of ﬁve cycles (5 ml
per cycle). One ml of the eluent was analyzed using an Agilent
Technologies gas chromatograph (GC) ﬁttedwith a ﬂame ionization
detector and HP-INNOWAX GC column with 1 mm ﬁlm thickness,
30 m long, 0.53 mm I.D. (J&W Scientiﬁc, Folsom, CA, USA). The GC
temperature programwas as follows: After equilibration at 100 C,
the temperature was held for 2 min, subsequently increased by
5 C/min to 150 C, held for 3min, increased by 20 C/min to 200 C,
then held again for another 3 min.
All quantiﬁcation was based on a series of calibration standards
containing N-heptadecane as the internal standard along with
analytical grade L-Menthol (99.0%, Sigma-Aldrich, St. Louis, MO,
USA) at 0.5e6 ng/mL. All quantitated extracts werewithin this range
and diluted if necessary.
2.6. Biological parameters
All parameters speciﬁed in OECD TG 413 were assayed with a
focus on local effects in the respiratory tract in the OECD groups
only (see 2.3). To provide an estimate of the test atmosphere con-
centration and bio-monitoring, nicotine and cotinine in plasma, as
well as menthol and its metabolite p-menthane-3,8-diol (M-I) in
plasma, were analyzed by Analytisch-biologisches Forschungslabor
(ABF, Munich, Germany); Nicotine and cotinine in plasma was
determined according to Piller et al. (2014); Menthol was deter-
mined from plasma after mixing with internal standard solution
(menthol-d4). Enzymatic hydrolysis with 10 ml glucuronidase was
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Headspace-SPME procedure for 20 min at 80 C, GC-MS analysis
was performed in selected ion monitoring (SIM) mode. Menthol
was quantiﬁed using a GC-MS system with an electron impact (EI)
ionization source. For the determination of M-I, internal standard
((þ)-cis-p-Menthan-3,8-diol) was added to plasma and hydrolyzed
as mentioned above. After protein precipitation, supernatants are
injected onto the LC-MS/MS system. Furthermore, the steady-state
blood carboxyhemoglobin (COHb) concentration, respiratory
physiology parameters, and representative urine nicotine metab-
olites, as well as biomarkers of exposure, were determined (as
described in Wong et al. (2016 (in this issue)). Food consumption
and body weight, as well as hematological, clinical-chemical, gross
pathological (as described in Wong et al. (2016 (in this issue)),
histopathological, and pulmonary inﬂammation parameters
(described below), were determined to characterize the biological
activity of the aerosols.
2.6.1. Lung lavage and analysis
BALF was collected from the right lung at the end of the 90-day
inhalation period using ﬁve consecutive cycles of ﬁlling and
emptying. For the ﬁrst cycle, pre-warmed calcium- and
magnesium-free phosphate-buffered saline (PBS) was used. For
cycles 2e5, bovine serum albumin (BSA) was added to the PBS. The
lavage ﬂuid of the ﬁrst cycle was collected separately, centrifuged,
and the supernatant fractionwas frozen in aliquots (below 60 C)
and submitted to Myriad Rules-Based Medicine (Austin, TX, USA)
for exploratory (non-GLP) analyses of a panel of selected proteins
(RodentMAP® v3.0).
Cell pellets from the ﬁrst lavage cycle were re-suspended in ice-
cold PBS/BSA and pooled into the BALF from cycles 2e5. The
number and viability of the free lung cells were determined, and
they were further differentiated by ﬂow cytometry (FACSCanto II,
Becton, Dickinson and Company, USA) into alveolar macrophages,
neutrophils, lymphocytes, and eosinophils after staining with cell-
type speciﬁc antibodies; for details, see (Friedrichs et al., 2006).
2.6.2. Necropsy, gross pathology, and organ weights
Full necropsy was performed without prior fasting the day after
the last exposure, according to previously described methods
(Vanscheeuwijck et al., 2002). The weight of the spleen, thymus,
lung with larynx and trachea, heart, kidneys, adrenal glands, testis,
brain, and liver was determined. Paired organs were weighed
separately.
2.6.3. Histopathology
To assess systemic effects, including inﬂammation, histological
examinations of the following non-respiratory tract organs were
performed (sham, 3R4F, MRC(HM), and THS2.2M(H)): Liver, kidney,
adrenal glands, heart, brain, testes, spleen, thymus, lymph nodes
(bronchial, mediastinal, and mesenterial), sternum with bone
marrow, jejunum (including Peyer's patches), and skin. Non-
respiratory tract organs were ﬁxed in 4% formaldehyde, except
for the sternum and testes, which were ﬁxed in Schaffer's and
Bouin solutions, respectively.
Histopathological evaluation was performed to investigate local
effects in respiratory tract organs, i.e. nasal passages with nasal-
associated lymphoid tissue, larynx, trachea, and lungs. After
weight determination, the right lung was separated for BALF
extraction. Fixation and histoprocessing of the left lung was per-
formed as described previously (Vanscheeuwijck et al., 2002),
although the ﬁxative was replaced by ethanol glycerol acetic acid
formaldehyde saline (EGAFS) solution. Histological sections of
respiratory tract organs were prepared at deﬁned levels (see below)
and stained with hematoxylin and eosin (H&E) (Terpstra et al.,2003). Sections from the nose at levels 1 to 4, the trachea at level
4 (bifurcation), and the left lung stained with Alcian blue/periodic
acid-Schiff reagent were evaluated histopathologically. The laryn-
geal epithelial thickness was determined at the ﬂoor of the larynx
and at the lower medial region of the vocal cords (level of arytenoid
projections).
Histopathological evaluation of the respiratory tract was per-
formed according to a deﬁned grading system (0 ¼ no ﬁnding;
1 ¼ slight; 2 ¼ slight/moderate; 3 ¼ moderate; 4 ¼ moderate/
marked; 5 ¼marked) (Terpstra et al., 2003). The nature of some of
the endpoints only allowed the evaluation of incidences, which
were recorded separately. Slides were evaluated in a blinded
manner (without knowledge of treatment groups) by a board-
certiﬁed veterinary pathologist with experience in CS-related
changes in the respiratory tract of rodents.
2.6.4. Statistical evaluation
Various comparisons between groups were performed. This was
made separately per sex (comparisons between sexes were thus
not performed). For each sex, all exposed groups were compared to
the sham group. In addition, all THS2.2M-exposed groups were
compared to MRC-exposed groups and, ﬁnally, MRC-exposed
groups were compared against the 3R4F-exposed group to inves-
tigate whether the designed MRCs had a comparable toxicological
effect in rats as the classical 3R4F reference cigarette. Both MRC
groups were also compared with the 3R4F-exposed group to
investigate whether the designed MRCs had a comparable toxico-
logical effect in rats as the classical 3R4F reference cigarette.
Descriptive statistics (N, mean or median, standard deviation or
geometric standard deviation) of the main aerosol parameters
(TPM, CO, nicotine, formaldehyde, acetaldehyde, acrolein, and
particle size distribution) were computed for each exposure
chamber. For the parameters of bio-monitoring and exposure
(blood COHb, selected nicotine and aerosol metabolites in urine,
and respiratory physiology), descriptive statistics (number of valid
measurements, mean, standard deviation or standard error of the
mean) were computed for each exposure group and sex, and when
relevant, for various time points.
For biological endpoints (body weight, food consumption, lung
inﬂammation, hematology, clinical chemistry, organ weight and
pathology), descriptive statistics were computed for each exposure
group and sex, and when relevant, for various time points. For
parameters evaluated on a continuous scale (e.g. body weight,
hematology), basic statistics (number of valid measurements,
mean, standard deviation, standard error of the mean) were
computed. For ordinal parameters (e.g. histopathological scores),
the number of valid measurements and a frequency table (absolute
and relative to the number of valid observations) were computed,
as well as the mean and standard deviation or standard error of the
mean. For incidence parameters, the number of valid measure-
ments and a frequency table (absolute and relative to the number of
valid observations) were computed.
Additionally and separately for each sex, pairwise differences
between groups were estimated. For continuous variables, this was
done by means of a t-test (potentially accounting for variance
heterogeneity) associated with 95% conﬁdence intervals or,
depending on the normality of the data, either a parametric test
(ANOVA) or a non-parametric test was performed. For incidences,
this was done using Fisher's exact test. For ordinal variables, this
was done by the Cochran-Mantel-Haenszel test, using the row
mean scores statistic (with the alternative hypothesis that mean
responses differ across compared groups, the scores being deﬁned
as integer scores). Finally, for data from multi-analyte proﬁles in
BALF, as the number of values below the limit of detection/quan-
tiﬁcation was high for some analytes, a Mann-Whitney-Wilcoxon
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2.7. Tissue preparation for systems toxicology endpoints (“OECD
plus”)
Dissection took take place 16e24 h after the last exposure. Prior
to organ removal, a whole body perfusion with cold saline was
performed. In short, after setting the ﬂow rate of a peristaltic pump
at 60 ml/min, a needle was inserted in the left ventricle and then a
small incision was performed at the right atrium of the heart.
Perfusion was performed for approximately 8 min until organs
turned pale. For transcriptomics analysis, RNE was isolated from
the left side of the nose. For proteomics analysis, the RNE was
isolated from the right side. The left lung lobe was cryo-sectioned
into 40 mm thick slices, and the slices were collected alternating
for transcriptomics and proteomics (and backup) analysis.
2.8. Transcriptomics
RNA fromRNE and lung samples was isolated using RNeasyMini
extraction kit (Qiagen, Hilden, Germany). RNA was processed for
hybridization on GeneChip® Rat Genome 230 2.0 Arrays (Affyme-
trix, Santa Clara, CA, USA) by using the High Throughput 30 In Vitro
Transcription PLUS kit (Affymetrix). Further details can be found in
our accompanying manuscript (Kogel et al., 2014). Raw CEL ﬁles
were background-corrected, normalized, and summarized using
frozen Robust Multiarray Analysis (fRMA) (McCall et al., 2010). To
identify genes that were differentially expressed, a linear model
was ﬁtted for each exposure condition and its respective sham
group, and p-values from a moderated t-statistic were calculated
with the empirical Bayes approach (Gentleman et al., 2004). The
Benjamini-Hochberg False Discovery Rate (FDR) method was then
used to correct for multiple testing effects. Genes with an adjusted
p-value <0.05 were considered differentially expressed.
A heatmap of the log2 transformed gene expression fold-
changes (FC) between samples exposed to MA and the corre-
sponding samples exposed to sham was generated, using the
heatmap.2 function in the gplots R package (Warnes et al., 2012). A
gene was deﬁned as differentially expressed if its FDR <0.05. Fold-
change was set to zero for all the non-differentially expressed
genes.
2.9. Proteomics
Proteome alterations were assessed by isobaric tag-based
quantiﬁcation using the iTRAQ® approach. The full details of the
method are given in our accompanying manuscript (Sewer et al.,
2016 (in this issue)). Brieﬂy, two multiplexed iTRAQ analysis sets
were prepared to allow for all relevant comparisons: iTRAQ set 1
contained all samples of the 90-day time point, and iTRAQ set 2 was
focused on the exposure and 90 þ 42d recovery effects for female
rats only. RNE samples were homogenized and sonicated in tissue
lysis buffer (Bio-Rad, Hercules, CA, USA) in random order, and the
proteins were precipitated with acetone. Frozen rat lung tissue was
homogenized with a bead-assisted procedure in TissueLyser II
(Qiagen, Hilden, Germany) in tissue lysis buffer before acetone
precipitation. Protein precipitates were processed for the iTRAQ 8-
plex labeling procedure according to the manufacturer's in-
structions (SCIEX, Framingham, MA, USA).
Samples were analyzed in random order using an Easy-nanoLC
1000 liquid chromatograph (Thermo Scientiﬁc, Waltham, MA,
USA) connected online to a Q Exactive (Thermo Scientiﬁc) mass
analyzer. Mass spectrometry runs were processed and quantiﬁed
using Proteome Discoverer version 1.4.0.288 software (Thermo
Scientiﬁc) and custom software. For the detection of differentiallyexpressed proteins, a linear model was ﬁtted for each exposure
condition and its respective sham group, and p-values from a
moderated t-statistic were calculated with the empirical Bayes
approach (Gentleman et al., 2004). The Benjamini-Hochberg FDR
method was then used to correct for multiple testing effects. Pro-
teins with an adjusted p-value <0.05 were considered differentially
expressed.
3. Results
3.1. Test atmosphere composition
Analysis of the test atmospheres throughout the 90-day inha-
lation period indicated that the target nicotine concentration for all
groups was achieved, and was within ±10% of target values. Daily
concentrations of TPM and CO were also reproducible and within a
variation of ±10% throughout the entire exposure period. MA
generated from THS2.2M contained approximately only 50% of the
TPM and only 2% of the COmeasured in MS fromMRCs at the same
nicotine concentration.
The particle size distribution measurements indicated that
particles were equally respirable in all MS- and MA-exposed
groups: The mass median aerodynamic diameter (MMAD) ranged
from 0.62 to 0.71 mm (geometrical standard deviation (GSD) from
1.33 to 1.52) in the test atmosphere from MRCs and THS2.2M.
At equal nicotine concentrations, the quantities of formaldehyde
and acetaldehyde present in THS2.2M MAwere approximately 85%
and 78% lower, respectively, compared with MS from MRCs; acro-
lein levels in THS2.2M MA were lower by more than 90%.
The menthol concentration in diluted MS from the low MRC
matched the concentration from the medium THS2.2M, whereas
the menthol concentration in MS from the high MRC reached
approximately 75% of the high THS2.2M concentration.
A detailed analysis of the test atmospheres generated from
THS2.2M and MRCs, is given in Table 1.
Test atmosphere characteristics for the 3R4F reference cigarette
(Table 1) were in accordance with those determined in other
studies (Wong et al., 2016 (in this issue)).
3.2. Bio-monitoring
3.2.1. Respiratory physiology
Because of a technical error in the equipment setup, it was only
possible to measure respiratory frequencies. Data are shown in
Tables 2a and 2b.
The respiratory frequencies of the male and female rats exposed
to MRC(LM) and MRC(HM) were statistically signiﬁcantly lower
than those in sham-exposed male and female rats (p < 0.05 and
p < 0.01, respectively). In contrast, the respiratory frequencies of
rats exposed to THS2.2M MA remained unaffected compared with
sham, and were statistically signiﬁcantly higher in the female
THS2.2M Medium group compared with the MRC(LM) group,
indicating that MS fromMRCmay have a higher irritant power than
MA from THS2.2M. No menthol-related differences were observ-
able in respiratory frequency in MRC-groups compared with the
3R4F group.
3.2.2. Carboxyhemoglobin
The steady-state concentration of COHb in blood was up to
26.5% in rats exposed to MRCs and up to 4.6% in rats exposed to
THS2.2M (Tables 2a and 2b). COHb levels in MRC MS-exposed an-
imals were comparable to 3R4F, and are in line with our historical
data for 3R4F MS inhalation (Wong et al. (in this issue)), indicating
efﬁcient uptake of the aerosols by the animals. COHb in male
THS2.2M MA-exposed rats showed no statistically signiﬁcant
Table 1
Characterization of test atmospheres e determinations performed in the exposure chambers.
Group TPM (mg/l) Particle size distribution Nicotine
(mg/l)
Carbon
monoxide (ppm)
Formaldehyde
(mg/l)
Acetaldehyde
(mg/l)
Acrolein
(mg/l)
Menthol in diluted
aerosol (mg/l)
MMAD (mm) GSD
Sham 0 0 0 0 <LOQ <LOQ <LOQ <LOQ <LOQ
3R4F 303.9 ± 16.5 0.670e0.751 1.23e1.96 22.67 ± 1.65 362.59 ± 21.80 0.6 ± 0.11 17.47 ± 2.25 1.8 ± 0.18 <LOQ
MRC (LM) 335.8 ± 14.6 0.669e0.728 1.22e1.77 22.92 ± 1.20 375.19 ± 23.88 0.89 ± 0.18 15.7 ± 3.2 1.73 ± 0.31 56.12 ± 2.24
MRC(HM) 342.5 ± 14.2 0.670e0.718 1.23e2.53 22.17 ± 1.03 372.15 ± 15.96 0.89 ± 0.25 14.95 ± 4.46 1.66 ± 0.46 80.22 ± 1.64
THS2.2M Low 88.6 ± 4.7 0.601e0.666 1.16e2.78 14.5 2 ± 0.54 4.76 ± 0.25 0.09 ± 0.01 2.25 ± 0.15 0.08 ± 0.01 32.68 ± 1.9
THS2.2M Medium 143.3 ± 8.7 0.604e0.787 1.40e4.94 22.60 ± 1.10 6.80 ± 0.60 0.14 ± 0.02 3.48 ± 0.3 0.14 ± 0.01 48.87 ± 2.08
THS2.2M High 370.4 ± 26.7 0.606e0.626 1.20e2.18 49.26 ± 2.57 16.8 1 ± 0.92 0.34 ± 0.04 8.04 ± 0.71 0.36 ± 0.04 109.14 ± 8.74
Results represent mean ± standard deviation. Abbreviations: TPM, total particulate matter; MMAD, mass median aerodynamic diameter; GSD, geometric standard deviation;
LOQ, lower limit of quantiﬁcation.
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proportions of COHb that were statistically signiﬁcant were
observed in females in the THS2.2M Medium and THS2.2M High
groups. Similarly higher proportions of COHb were found in the
male rats exposed to these test atmospheres, though without
reaching statistically signiﬁcant differences. Measurements
repeated at the end of the recovery period showed that all COHb
values were at basal levels.3.2.3. Nicotine metabolites in urine
The quantities of nicotine metabolites (nornicotine (NNIC),
norcotinine (NCOT), 3’-hydroxycotinine (30HOCOT), cotinine (COT),
and nicotine-N0-oxide (NN0O)) were determined in 24-h urine
(Tables 2a and 2b). As controls, nicotine metabolites were deter-
mined in urine samples collected before the 90-day exposure phase
and during the 42-day recovery phase. The results obtained were
all below the limit of quantiﬁcation, and were as follows (in mmol/
l): NNIC: 1.746, NCOT: 0.906, 30HOCOT: 1.734, COT: 1.307, NN’O:
5.225 (data not shown). The total quantities of nicotine metabolites
excreted were comparable between the two MRC groups, and did
not differ from the 3R4F group. In THS2.2M-exposed rats, the total
quantities of nicotine metabolites excreted were comparable be-
tween male and female rats, and proportional to the nicotine test
atmosphere concentrations, except for the THS2.2M Medium fe-
male group. At equal nicotine concentrations in the test atmo-
sphere, the total quantities of nicotine metabolites excreted were
higher in the THS2.2MMedium group than in theMRCMS-exposed
rats. This suggests an overall higher uptake of aerosol constituents
in the THS2.2M MA-exposed rats.
The relative distribution of the ﬁve nicotine metabolites
measured (data not shown) was similar in all groups, indicating
similar metabolism, in line with results observed in previous
studies (Vanscheeuwijck et al., 2002).
There was no menthol effect on the level of nicotine metabolites
observed in the MRC groups compared with 3R4F.
Biomarkers of exposure, including 2-cyanoethylmercapturic
acid (CEMA) (metabolite of acrylonitrile), 3-
hydroxypropylmercapturic acid (HPMA) (metabolite of acrolein),
total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
(metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK)), and S-phenylmercapturic acid (SPMA) (metabolite of ben-
zene), were quantiﬁed in 24-h urine (Tables 2a and 2b). The con-
centrations of biomarkers in sham animals during exposure and in
the urine of rats collected before the start of the exposure period
were very low, with the exception of HPMA due to endogenous
production of acrolein (as a metabolic product) in normal rats
(Stevens and Maier, 2008). During exposure, the quantity of HPMA
was at least 2-fold lower in the THS2.2M-exposed groups than in
the MRC groups at equal nicotine exposure concentrations. The
quantities of CEMA, SPMA, and NNAL were 40-fold, 46-fold, and 4-fold lower, respectively, in the THS2.2M-exposed groups than in the
reference groups at equal nicotine exposure concentrations.
No menthol-related differences were observed for any of the
biomarkers in urine in MRC groups compared with the 3R4F group.
3.2.4. Biomarkers of exposure in blood
Biomarkers of exposure in blood included nicotine and cotinine,
as well as menthol and its metabolite p-menthane-3,8-diol (M-I) in
plasma (Tables 3a and 3b). In THS2.2MA-exposed groups, a trend of
higher nicotine and cotinine levels in plasma was observed, in
function of higher test atmosphere nicotine concentrations. The
concentration of nicotine and cotinine in plasma in the THS2.2M
Medium groups was increased 1.5-fold and 1.2-fold, respectively, in
male rats, and 1.2-fold in female rats compared with the THS2.2M
Low groups. In the THS2.2M High groups, nicotine and cotinine
levels were 3.3-fold and 1.8-fold higher, respectively, in male rats,
and 2.8-fold and 2.0-fold higher, respectively, in female rats,
compared with the THS2.2M Low groups.
Female rats showed higher levels of nicotine and cotinine in
serum relative to male rats.
The uptake of menthol was veriﬁed by quantiﬁcation of menthol
and M-I in plasma. The observed serum menthol and M-I concen-
trations showed a concentration-dependent response in the
THS2.2M MA- and MRC MS-exposed rats. In line with the test at-
mosphere data, menthol and M-I levels in blood were lower in the
MRC(HM) group compared with the THS2.2M High group.
The levels of menthol in the MRC had no observable inﬂuence
on the nicotine or cotinine levels in serum, and values were com-
parable to those in 3R4F.
3.3. In-life observations, clinical observations
Clinical observations after daily exposure included harderian
gland secretion and wet fur, which were frequently observed in
sham and all MA/MS-exposed groups, whereas nasal discharge and
closed eyelids were seen in MS-exposed groups only. Overall,
similar clinical observations have been noted in previous rat
inhalation studies with cigarette smoke (Schramke et al., 2014) and
are known to be related to tube restraint and/or the irritant ca-
pacity of cigarette smoke.
Body weight (BW) development revealed an exposure-related
reduction for MRC-exposed male rats during the 90-day inhala-
tion period (Fig. 1); BW was statistically signiﬁcantly lower by 18%
at the end of the 90-day exposure period for all MRC MS-exposed
groups, as well as for the 3R4F group (17% lower), indicating that
there was no menthol-related effect on BW development.
BW development of THS2.2M-exposed male rats started to
differ from the sham group on study day 50; the BWof all THS2.2M
groups were clustered together, and were statistically signiﬁcantly
lower by 9e11% compared with sham. At equivalent nicotine
Table 2a
Body weights and bio-monitoring parameters measured during the 90-day exposure period to test atmosphere.
Parameter Sham 3R4F MRC(LM) MRC(HM) THS2.2M Low THS2.2M Medium THS2.2M High
Body weight (day 89) [g] M 448 ± 12.7 [9] 374 ± 8.5 [10] *** 370 ± 13.1 [10]*** 366 ± 10.7 [10] *** 403 ± 8.5 [10]* 409 ± 12.5 [10] 404 ± 15.8 [8]
F 249 ± 6.2 [10] 270 ± 5.5 [8]** 272 ± 9.2 [10] 263 ± 6.6 [9]* 277 ± 8.9 [10]* 283 ± 3.2 [10]*** 282 ± 8.6 [10]**
Respiratory frequency [breaths min1] M 142.34 ± 8.38 [9] 116.16 ± 3.89 [9] * 120.21 ± 6.08 [10]* 117.38 ± 2.74 [10] * 133.21 ± 7.06 [10] 141.3 ± 9 [10] 127 ± 6.9 [8]
F 140.44 ± 10.2 [10] 102.05 ± 5.25 [10] ** 101.16 ± 5.88 [9] ** 105.48 ± 4.33 [10] ** 134.3 ± 5.42 [10] 145.9 ± 7.8 [8] 116.5 ± 5.6 [10]
COHb [%] M 3.65 ± 0.22 [10] 27 ± 0.82 [8] *** 22.31 ± 0.8 [8] *** 26.49 ± 0.68 [7] *** 3.44 ± 0.05 [10] 3.7 ± 0.1 [10] 4.3 ± 0.05 [9]
F 3.12 ± 0.03 [6] 26.2 ± 1 [3] ** 22.54 ± 1.35 [7] *** 24.07 ± 1.68 [7] *** 2.94 ± 0.15 [8] 3.6 ± 0.1 [10] ** 4.26 ± 0.1 [7] ***
CEMA in urine [ng/ml] M 5.49 ± 0.56 [10] 802.28 ± 114.6 [10] *** 715.62 ± 112.7 [10] *** 765.21 ± 111.39 [10] *** 11.32 ± 1.21 [10] ** 12.2 ± 1.1 [10] ** 17.65 ± 2.8 [10] ***
F 178.4 ± 115.8 [10] 858.22 ± 95.18 [10] *** 812.9 ± 116.01 [10] *** 436.46 ± 116.59 [10] *** 6.36 ± 0.6 [10] *** 9 ± 0.9 [10] ** 362.4 ± 248.4 [10] **
SPMA in urine [ng/ml] M 3.81 ± 0.46 [10] 478.13 ± 53.94 [10] *** 505.35 ± 62.06 [10] *** 610.83 ± 89.85 [10] *** 6.56 ± 0.89 [10] * 7.1 ± 0.6 [10] *** 11.23 ± 1.75 [10] **
F 91.74 ± 59.72 [10] 391.81 ± 52.95 [10] ** 370.72 ± 36.68 [10] ** 302.81 ± 81.12 [10] ** 3.31 ± 0.33 [10] 5.3 ± 0.6 [10] 116.13 ± 73.6 [10] *
NNAL in urine [pg/ml] M 0.85 ± 0 [10] 715.5 ± 95.4 [10] *** 509.2 ± 89.3 [10] *** 610.4 ± 93 [10] *** 21.9 ± 5.3 [10] ** 35.1 ± 8.4 [10] ** 134.4 ± 40.5 [10] ***
F 253.9 ± 170.9 [10] 803 ± 117.5 [10] * 465.7 ± 58.9 [10] * 295.3 ± 64.1 [10] * 30.8 ± 8.2 [10] 47.4 ± 10.2 [10] * 380.4 ± 241.7 [10] *
HPMA in urine [ng/ml] M 2932.3 ± 307.2 [10] 12098.7 ± 1912 [10] *** 13058.7 ± 1486 [10] *** 13297.7 ± 2557.8 [10] ** 4373.2 ± 480.1 [10] 5235.5 ± 794.5 [10] 5762.4 ± 804.9 [10]
F 4544.6 ± 1439 [10] 11749.5 ± 1442 [10] ** 11315.4 ± 1182 [10] ** 10086.7 ± 1583 [10] * 3078.3 ± 463 [10] 4883.8 ± 969 [10] 6586.5 ± 2205 [10]
Total nicotine metabolites in urine [nmol] M 9.02 ± 1.4 [10] 1982.2 ± 97.3 [10] *** 2852.9 ± 161.6 [10] *** 2367.5 ± 211.6 [10] *** 2752.9 ± 182.3 [10] *** 4618.8 ± 539.1 [10] *** 7934.9 ± 328.4 [10] ***
F 7.7 ± 1.1 [10] 2437.5 ± 168 [10] *** 3107.4 ± 333.5 [10] *** 2280.2 ± 114.6 [10] *** 2656.1 ± 342.8 [10] *** 3228.6 ± 293.3 [10] *** 8186.7 ± 707.7 [10] ***
Nicotine in plasma [ng/ml] M 1.92 ± 0.48 [10] 306.9 ± 22.75 [10] *** 281.04 ± 25.04 [10] *** 263.09 ± 17.89 [10] *** 231 ± 17 [10] *** 340.5 ± 18.3 [10] *** 762 ± 70.7 [10] ***
F 2.46 ± 0.33 [10] 509.26 ± 64.61 [10] *** 441.2 ± 29.79 [10] *** 486.96 ± 81.26 [10] *** 431 ± 40.2 [10] *** 590.6 ± 46.3 [10] *** 1207.7 ± 81.4 [10] ***
Cotinine in plasma [ng/ml] M 1.51 ± 0.13 [10] 509.26 ± 20.97 [10] *** 569.01 ± 19.98 [10] *** 526.02 ± 29.95 [10] *** 737.9 ± 31.9 [10] *** 875.2 ± 36.8 [10] *** 1335.5 ± 53.2 [10] ***
F 2.06 ± 0.49 [10] 591.88 ± 41.82 [10] *** 608.9 ± 27.9 [10] *** 603.39 ± 41.44 [10] *** 705.3 ± 35.3 [10] *** 828.6 ± 29.2 [10] *** 1398.5 ± 106.3 [10] ***
Menthol in plasma [ng/ml] M 17.75 ± 0 [10] 17.75 ± 0 [10] - 327.52 ± 34.51 [10] *** 453.88 ± 35.62 [10] *** 116.3 ± 10.3 [10] *** 229.1 ± 24.8 [10] 732.25 ± 75.6 [10]
F 17.75 ± 0 [10] 17.75 ± 0 [10] 609.35 ± 106 [10] *** 850.06 ± 179.9 [10] *** 169.3 ± 11.4 [10] *** 317.7 ± 33.3 [10] 971.5 ± 113. [10]
M-I in plasma [ng/ml] M 0.85 ± 0 [10] 0.85 ± 0 [10]e 150.84 ± 18.54 [10] *** 217.49 ± 24.4 [10] *** 126.6 ± 17.4 [10] *** 192.4 ± 46.6 [10] 309.4 ± 48.7 [10]
F 0.85 ± 0 [10] 0.85 ± 0 [10]e 242.6 ± 39.4 [10]*** 358.28 ± 84.7 [10] *** 211.9 ± 26.1 [10] *** 305.1 ± 40.7 [10] 434. ± 59.9 [10]
Results represent mean ± standard error. Abbreviations and limits od detection/quantiﬁcation: M, male; F, female; LM, low menthol; HM, high menthol; COHb, carboxyhemoglobin; LOQ, limit of quantiﬁcation; LOD, limit of
detection; HPMA, 3-hydroxypropylmercapturic acid (biomarker for acrolein uptake; LOD 12.6 ng/ml; LOQ 25 ng/ml); NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total, biomarker for NNK uptake; LOD 1.7 pg/ml; LOQ
5.0 pg/ml); SPMA, S-phenylmercapturic acid (biomarker for benzene uptake; LOD 0.005 ng/ml; LOQ 0.02 ng/ml); CEMA, 2-cyanoethylmercapturic acid (marker for acrylonitrile uptake; LOD 0.08 ng/ml; LOQ 0.25 ng/ml); MI, p-
menthane-3,8-diol (LOD 1.7 ng/ml; LOQ 5 ng/ml). Nicotine (LOD 1.0 ng/ml; LOQ 2.0 ng/ml); Cotinine (LOD 0.5 ng/l; LOQ 2.0 ng/l). Menthol (LOD 35.5 ng/l; LOQ 100 ng/l). The sample size is in parentheses. Difference from sham
group at 90d: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001.
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Table 2b
Statistically signiﬁcant differences for body weights and bio-monitoring parameters.
Parameter THS2.2M medium vs.MRC(LM) THS2.2M high vs. MRC(HM). MRC (HM) vs. 3R4F
Body weight (day 89)[g] M [* [** ¼
F ¼ [* ¼
Respiratory frequency [min1] M ¼ ¼ ¼
F [*** ¼ ¼
COHb [%] M Y*** Y*** ¼
F Y*** Y*** ¼
Total nicotine metabolites in urine [nmol] M [** [*** ¼
F [*** [*** ¼
CEMA in urine [ng/ml] M Y*** Y*** ¼
F Y*** ¼¼ Y*
SPMA in urine [ng/ml] M Y*** Y*** ¼
F Y*** ¼ ¼
NNAL in urine [pg/ml] M Y*** Y*** ¼
F Y*** ¼ Y**
HPMA in urine [ng/ml] M Y*** Y* ¼
F Y*** ¼ ¼
Nicotine in plasma [ng/ml] M ¼ [*** ¼
F [* [*** ¼
Cotinine in plasma [ng/ml] M [*** [*** ¼
F [*** [*** ¼
Menthol in plasma [ng/ml] M Y* [** [***
F Y* ¼ [***
MI in plasma [ng/ml] M ¼ [* [***
F ¼ ¼ [***
Difference between groups: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Symbols, Y indicates lower response in group 1 than in 2; [ indicates higher response in group 1
than in 2; ¼ indicates no signiﬁcance. Abbreviations: M, male; F, female; LM, low menthol; HM, high menthol; COHb, carboxyhemoglobin; HPMA, 3-
hydroxypropylmercapturic acid; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; SPMA, S-phenylmercapturic acid; CEMA, 2-cyanoethylmercapturic acid; MI, p-
menthane-3,8-diol.
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signiﬁcantly higher compared with MRC-exposed rats after 90
days. The body weights at the end of the inhalation period (day 89)
are shown in Tables 2a and 2b.
BW development in female rats did not show any treatment-
related differences from the sham group, which is consistent with
results from previous studies (Coggins, 1993; Coggins et al., 1989;
Vanscheeuwijck et al., 2002).
After the 42-day post-inhalation period, the progression of BW
across all exposure groupswas similar to that of sham for bothmale
and female rats, and there was no statistically signiﬁcant difference
between them.
Food consumption was statistically signiﬁcantly higher in all
THS2.2M MA-exposed groups compared with sham.
Clinical chemistry (Tables 3a and 3b) in MRC MS-exposed
groups revealed higher activity of the liver enzyme alkaline phos-
phatase. The concentrations of total cholesterol, triglycerides, and
glucose were consistently signiﬁcantly lower in both sexes
compared with sham, as also observed in previous studies
(Schramke et al., 2014; Terpstra et al., 2003; Vanscheeuwijck et al.,
2002). Similar effects were seen in the THS2.2M-exposed rats, and
were dependent on the exposure concentration. These changes
seem to be due to nicotine, as demonstrated in a previous study
investigating the effects of nebulized nicotine and nicotine pyru-
vate in a 28-day inhalation experiment (Phillips et al., 2015a).
In all MRC MS- or THS2.2M MA-exposed groups, other sporadic
effects were seen in either males or females (Tables 3aa and 3b).
After the post-inhalation period, most exposure-induced effects
were reversed.
Hematology analysis (Tables 4a and 4b) revealed statistically
signiﬁcant differences of the MA/MS-exposed groups compared
with sham, which were consistently higher for both sexes for the
number of neutrophils. Lymphocyte counts were also statistically
signiﬁcantly lower in all MRC groups, in THS2.2M female rats, and
in THS2.2M High male rats. In addition, female rats exposed to MRC
MS showed a statistically signiﬁcantly higher reticulocyte countthan sham.
Other changes were occasionally statistically signiﬁcantly
different, but in the range of those found in the sham or in the
historical range from previous inhalation studies.
Organweight changes in MS-exposed groups (Tables 5a and 5b)
exhibited typical MS exposure-related effects in accordance with
previously reported ﬁndings (Carmines and Gaworski, 2005;
Terpstra et al., 2003; Vanscheeuwijck et al., 2002). There were
statistically signiﬁcant changes in the relative weight (organweight
relative to exsanguinated body weight) of certain organs for all
exposure groups compared with sham, including adrenals, thymus,
uterus, ovaries, and kidney and lung with trachea and larynx.
However, relative weights of lung with trachea and larynx were
statistically signiﬁcantly lower in THS2.2M groups compared with
MRC groups. Higher relative organweight of testis was observed for
MRC groups and the THS2.2M High group compared with sham,
and for heart in MRC groups only.
An increase in liver weight was observed in the THS2.2M
groups, which was statistically signiﬁcantly higher compared with
sham in all THS2.2M groups except for the male THS2.2M Low
group, showing an exposure concentration-dependent trend.
Furthermore, liver weights of MRC groups were also statistically
signiﬁcantly higher compared with sham, but did not differ from
liver weights in THS2.2M Medium groups.
In general, no differences were observed in body weight, clinical
chemistry, or organ weight results in MRC groups compared with
the 3R4F group. However, erythrocyte counts were statistically
signiﬁcantly higher in the male MRC(HM) group, and reticulocyte
counts were statistically signiﬁcantly higher in the female
MRC(HM) group compared with 3R4F. Relative organ weight of the
uterus was statistically signiﬁcantly lower in the female MRC(HM)
group compared with 3R4F.3.4. Free lung cell differentiation in BALF
Exposure to MRC caused a statistically signiﬁcantly higher total
Table 3a
Clinical chemistry parameters determined at the end of the 90-day and the post-inhalation periods.
Parameter 90 days 90 þ 42d
Sham 3R4F MRC(LM) MR HM) THS2.2M Low THS2.2M Medium THS2.2M High Sham R 3R4F R MRC(HM) R THS2.2M High R
Alanine amino -
transferase
(IU/L)
M 57.1 ± 6.4 [10] 62.6 ± 3.5 [9] 53.5 ± 2.8 [10] 59.9 3.6 [10] 58.4 ± 1.8 [10] 61.3 ± 4.2 [10] 77.2 ± 5.5 [10]** 50.3 ± 3.7 [8] 48.3 ± 3.7 [8] 45.3 ± 1.2 [8] 44 ± 1.8 [8]
F 57.65 ± 11.5[10] 66.75 ± 7 [8] 80.75 ± 14.9 [10]* 58.4 3.7 [9] 66.7 ± 3.5 [10]* 71.9 ± 5.5 [10] 62.3 ± 4.3 [10] 48.1 ± 3.8[7] 42.1 ± 3.6 [8] 44.4 ± 4.6 [8] 31.9 ± 2 [8]
Alkaline
phosphatase
(IU/l)
M 170.3 ± 13.5 [10] 249.8 ± 29.2 [9]* 253.4 ± 26.8 [10]* 203 ± 20 [10] 173.1 ± 13 [10] 185.5 ± 14.7 [10] 297.4 ± 24.9 [10]*** 130.3 ± 7.6 [8] 151.9 ± 21.3 [8] 127.9 ± 18.8 [8] 155.9 ± 18.3 [8]
F 126.5 ± 13.3 [10] 194.6 ± 19.5 [8]* 213.5 ± 19.2 [10]** 211 ± 21.4 [9]** 152.5 ± 15 [10] 151 ± 14.3 [10] 216.7 ± 17.7 [10]*** 85 ± 10.8 [7] 72.6 ± 13.2 [8] 88.9 ± 10.5 [8] 69.5 ± 8.7 [8]
Aspartate
amino-
transferase
(IU/l)
M 111.3 ± 16.8 [10] 127.9 ± 8.2 [9]* 118.7 ± 10.4 [10]* 139 ± 5.7 [10] 134.5 ± 8.1 [10] 127.6 ± 10.1 [10] 150.1 ± 13.4 [10]*** 114.6 ± 5.7 [8] 118.4 ± 10.9 [8] 83.1 ± 5 [8] 104.3 ± 8.2 [8]
F 147.1 ± 23.8 [10] 163.2 ± 13.5 [8] 204.8 ± 60.5 [10] 146 ± 17.8 [9] 129.3 ± 6.6 [10] 168 ± 28 [10] 135.9 ± 12.7 [10] 88.3 ± 4.3 [7] 95.3 ± 10.3 [8] 105.2 ± 11.1 [8] 75.7 ± 5.8 [8]
Calcium
(mmol/l)
M 2.4 ± 0.1 [10] 2.4 ± 0.05 [9] 2.4 ± 0.04 [10] 2.3 0.02 [10] 2.3 ± 0.0 [10] 2.3 ± 0.1 [10] 2.04 ± 0.1 [10] 2.4 ± 0.0 [8] 2.5 ± 0.02 [8] 2.5 ± 0.04 [8] 2.6 ± 0.1 [8]
F 2.4 ± 0.02 [10] 2.4 ± 0.0 [8]** 2.4 ± 0.0 [10] 2.4 0.0 [9] 2.3 ± 0.0 [10]* 2.3 ± 0.0 [10] 2.3 ± 0.0 [10]* 2.6 ± 0.1 [7] 2.6 ± 0.04 [8] 2.6 ± 0.05 [8] 2.6 ± 0.1 [8]
Creatinine
kinase (mol/l)
M 36.3 ± 2 [10] 32.2 ± 1.6 [9] 29.4 ± 2.1 [10]* 31.9 1.6 [10] 29.1 ± 1.6 [10]* 32.1 ± 2.3 [10] 29.6 ± 2.8 [10] 39.6 ± 1.8 [8] 38.3 ± 1.7 [8] 40.4 ± 1.1 [8] 43.5 ± 2.3 [8]
F 33.5 ± 2.2 [10] 29.3 ± 2.3 [8] 28.9 ± 3.3 [10]* 30.1 1.7 [9]* 26.6 ± 1.5 [10]** 27.8 ± 1.5 [10] 25 ± 1.7 [10] 36.7 ± 1.9 [7] 40 ± 1.0 [8] 36.5 ± 2.2 [8] 37 ± 1.9 [8]
Glucose
(mmol/l)
M 13.8 ± 0.8 [10] 9.5 ± 0.9 [9]** 9.6 ± 0.8 [10]** 8.9 0.5 [10]*** 11 ± 0.9 [10]* 10.1 ± 0.8 [10]** 10.4 ± 1.4 [10]* 12.1 ± 0.7 [8] 13.8 ± 1.1 [8] 15.2 ± 0.6 [8] 14.1 ± 1.5 [8]
F 10.9 ± 0.7 [10] 8.1 ± 0.6 [8]** 8.7 ± 0.7 [10]* 9 ± [9]* 8.8 ± 0.4 [10]* 8.8 ± 0.6 [10]* 7.9 ± 0.4 [10]** 10.4 ± 0.4 [7] 10.8 ± 0.7 [8] 9.9 ± 0.8 [8] 12.2 ± 1.5 [8]
Total cholesterol
(mmol/l)
M 1.22 ± 0.1 [10] 0.94 ± 0.0 [9]** 0.99 ± 0.0 [10]* 0.99 0.1 [10]* 0.94 ± 0.1 [10]* 0.91 ± 0.0 [10]** 1.11 ± 0.1 [10] 1.35 ± 0.1 [8] 1.39 ± 0.06 [8] 1.25 ± 0.1 [8] 1.47 ± 0.1 [8]
F 1.29 ± 0.1 [10] 0.81 ± 0.1 [8]** 0.72 ± 0.0 [10]*** 0.8 0.1 [9]*** 0.96 ± 0.1 [10]** 0.82 ± 0.1 [10]*** 1.02 ± 0.1 [10]* 1.28 ± 0.1 [7] 1.48 ± 0.1 [8] 1.17 ± 0.1 [8] 1.27 ± 0.1 [8]
Total protein
(g/l)
M 59.6 ± 1.4 [10] 61.3 ± 0.9 [9] 60.6 ± 0.8 [10] 60 ± 0.6 [10] 58.2 ± 1.4 [10] 57.5 ± 1.5 [10] 60.8 ± 1.2 [10] 61.9 ± 0.6 [8] 63.1 ± 1.4 [8] 65.1 ± 1.3 [8] 64.9 ± 1.4 [8]
F 65.3 ± 1.1 [10] 61.1 ± 1.1 [8]* 61 ± 1.5 [10]* 60.3 1 [9]** 58 ± 1.2 [10]*** 58.6 ± 0.9 [10]*** 59.2 ± 0.9 [10]*** 67 ± 1.5 [7] 67.6 ± 1 [8] 69.3 ± 1.3 [8] 66.1 ± 1.6 [8]
Triglycerides
(mmol/l)
M 0.99 ± 0.1 [10] 0.39 ± 0.1 [9]*** 0.48 ± 0.1 [10]*** 0.55 0.1 [10]*** 0.86 ± 0.1 [10] 0.75 ± 0.1 [10]** 0.6 ± 0.11 [10]** 0.92 ± 0.1 [8] 1.09 ± 0.2 [8] 1.05 ± 0.16 [8] 1.11 ± 0.2 [8]
F 0.77 ± 0.11 [10] 0.29 ± 0.1 [8]** 0.26 ± 0.0 [10]*** 0.24 0.0 [9]** 0.58 ± 0.1 [10] 0.41 ± 0.1 [10]* 0.4 ± 0.08 [10]* 1.37 ± 0.14 [7] 0.86 ± 0.1 [8] 0.9 ± 0.12 [8] 0.92 ± 0.1 [8]
Clinical chemistry parameters measured after 90-day exposure (90 days) and 42- ay recovery following a 90-day exposure period (90 þ 42d). Results represent mean ± standard error. The sample size is in parentheses.
Difference from sham group at 90 days: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p 0.001. Abbreviations: M, male; F, female; LM, low menthol; HM, high menthol; R, recovery groups.
Table 3b
Statistically signiﬁcant differences for bio-monitoring parameters at the end of th 90-day and post-inhalation periods.
Parameter THS2.2M Medium vs.MRC(LM) THS2.2M High vs. MRC(HM). MRC (HM) vs. 3R4F Sham R vs. Sham 3R4F R vs. 3R4F MRC(HM) R vs. MRC(HM) THS2.2M High R vs.
THS2.2M High
Alanine amino- - transferase activity (IU/L) M ¼ [* ¼ ¼ Y* Y** Y***
F ¼ ¼ ¼ ¼ Y* Y* Y***
Alkaline phosphatase activity (IU/L) M Y* [** ¼ Y* Y* Y** Y***
F Y* ¼ ¼ Y* Y*** Y*** Y***
Aspartate amino-transferase activity (IU/L) M ¼ ¼ ¼ ¼ ¼ Y*** Y*
F ¼ ¼ ¼ Y** Y** ¼ Y***
Calcium (mmol/L) M ¼ ¼ ¼ ¼ ¼ [*** [**
F ¼ ¼ ¼ [* [*** [** [**
Creatinine kinase (mol/L) M ¼ ¼ ¼ ¼ [* [*** [**
F ¼ ¼ ¼ ¼ [** [* [***
Glucose (mmol/L) M ¼ ¼ ¼ ¼ [** [*** ¼
F ¼ ¼ ¼ ¼ [* ¼ [***
Total cholesterol (mmol/L) M ¼ ¼ ¼ ¼ [*** [** [*
F ¼ ¼ ¼ ¼ [*** [** [*
Total protein (g/l) M ¼ ¼ ¼ ¼ ¼ [** [*
F ¼ ¼ ¼ ¼ [*** [*** [**
Triglycerides (mmol/L) M [** ¼ ¼ ¼ [** [* ¼
F [* ¼ ¼ [** [*** [*** [**
Difference between groups: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Symb s, Y indicates lower response in group 1 than in 2; [ indicates higher response in group 1 than in 2;¼ indicates no signiﬁcance. Abbreviations:
M, male; F, female; LM, low menthol; HM, high menthol; R, recovery groups.
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Fig. 1. Body weight development. Mean body weights of male (A) and female (B) rats exposed to fresh air (sham) and aerosols from THS2.2M, 3R4F, and MRC. Animals were
weighed twice per week. Day 1 represents the exposure start date. N¼6e20. Abbreviations: LM, low menthol; HM, high menthol.
A. Oviedo et al. / Regulatory Toxicology and Pharmacology 81 (2016) S93eS122 S103cell count in all groups compared with sham, including statistically
signiﬁcantly higher numbers of neutrophils, eosinophils, macro-
phages, and lymphocytes, all indicative of the presence of lung
inﬂammation (Tables 6a and 6b). In contrast, there was no
inﬂammation in the lungs of THS2.2M-exposed rats, as evidenced
by the absence of statistically signiﬁcant differences comparedwith
sham, even in the THS2.2M High group where the nicotine expo-
sure concentration was twice as high as in the MRC-exposed
groups.
At the end of the 42-day post-inhalation recovery period,
lymphocyte counts in MRC groups remained unchanged, and the
effects of the MRC MS-exposure on neutrophil counts and eosino-
phil counts were reduced but still present for both male and female
groups.
Similar results were observed in the 3R4F group at the end of
the exposure and recovery periods, and are consistent with ﬁndings
from past studies (Friedrichs et al., 2006; Smith et al., 2002; Werley
et al., 2008). Exposure to MRC(HM) caused a statistically signiﬁ-
cantly increase in total cell count and higher numbers ofneutrophils and macrophages in male rats compared with 3R4F
after the 90 days of exposure.3.5. Cytokines and chemokines in BALF
Multiple analyte proﬁling (RodentMAP™) was performed on
BALF to quantify 60 analytes; most analytes were below the lower
limit of quantiﬁcation or did not show exposure-related effects. The
fold-changes in concentrations of nine analytes in the BALF were
statistically signiﬁcantly elevated in MRC-exposed groups, pointing
to the presence of lung inﬂammation (Fig. 2). Both male and female
rats exposed to MRCs had higher levels of the following cytokines
and chemokines, which were present at the same magnitude in the
BALF of the 3R4F group: Resistin, vascular cell-adhesionmolecule-1
(VCAM1), MCP-1 (chemokine (C-C motif) ligand 2 (CCL2)), MCP3
(CCL7), MDC (CCL22), MIP-1beta (CCL4), macrophage colony-
stimulating factor (M-CSF-1 (M-CSF or CSF-1)), metalloproteinase
9 (MMP9), and ﬁbrinogen. All nine cytokines were markedly lower
or not present in the THS2.2M groups.
Table 4a
Hematological parameters at the end of the 90-day inhalation and post-inhalation periods.
Parameter 90 days 90 þ 42d
Sham 3R4F MRC(LM) MRC(HM) THS2.2M Low THS2.2M Medium THS2.2M High Sham R 3R4F R MRC(HM) R THS2.2M High R
Clotting
potential
Fibrinogen [s] M 18.4 ± 2.7 [7] 11.6 ± 1 [9]* 12 ± 0.6 [9] 12.5 ± 0.9 [10] 14.9 ± 0.7 [7] 14.7 ± 2 [10] 12.5 ± 1 [7] 17 ± 0.4 [7] 14.7 ± 1.5 [8] 18.3 ± 1 [8] 18.9 ± 3.7 [8]
F 22.2 ± 2.1 [8] 19.7 ± 6.8 [7] 14.2 ± 1.7 [9]** 11.4 ± 1.5 [7]** 16.2 ± 1 [10]* 14.8 ± 0.8 [10]** 15.3 ± 2.5 [8] 25.3 ± 1.5 [8] 23.4 ± 1.2 [8] 23.3 ± 2.1 [7] 26.5 ± 1.4 [8]
Fibrinogen [g/l] M 3.5 ± 0.9 [7] 4.8 ± 0.5 [9]* 4.4 ± 0.2 [9] 4.4 ± 0.3 [10]* 3.5 ± 0.2 [7] 4 ± 0.4 [10] 4.4 ± 0.4 [7] 3.1 ± 0.1 [7] 3.9 ± 0.6 [8] 2.9 ± 0.1 [8] 2.8 ± 0.4 [8]
F 2.3 ± 0.3 [8] 3.7 ± 0.7 [7] 4.3 ± 0.4 [9]** 4.9 ± 0.6 [7]** 3.3 ± 0.2 [10]* 3.6 ± 0.2 [10]** 4 ± 0.6 [8]* 1.9 ± 0.2 [8] 2.1 ± 0.2 [8] 1.8 ± 0.2 [7] 2 ± 0.1 [8]
Prothrombin time [s] M 15.8 ± 0.4 [7] 17.3 ± 0.4 [9]** 17.2 ± 0.4 [9]** 16.8 ± 0.4 [10]* 16.3 ± 0.5 [7]* 16.4 ± 0.4 [10] 16.2 ± 0.4 [7] 15.1 ± 0.4 [7] 15.1 ± 0.3 [8] 15.4 ± 0.2 [8] 16.4 ± 0.6 [8]
F 15.3 ± 0.3 [8] 16.9 ± 0.9 [7] 16.7 ± 0.3 [9]** 16.9 ± 0.6 [7]* 15.8 ± 0.3 [10] 16.2 ± 0.2 [10] 15.9 ± 0.4 [8] 15.1 ± 0.3 [8] 15.2 ± 0.3 [8] 15.1 ± 0.2 [7] 14.7 ± 0.2 [8]
Red blood
cells
Erythrocyte [106/ml] M 8.6 ± 0.3 [10] 8.5 ± 0.2 [9] 8.6 ± 0.2 [10] 9 ± 0.1 [10] 8.7 ± 0.2 [10] 8.4 ± 0.2 [10] 8.3 ± 0.2 [10] 8.4 ± 0.1 [8] 8 ± 0.2 [8] 8.4 ± 0.1 [8] 8.3 ± 0.1 [8]
F 8 ± 0.1 [10] 8.1 ± 0.1 [8] 7.9 ± 0.2 [10] 7.5 ± 0.2 [9]* 8 ± 0.2 [10] 7.5 ± 0.1 [10]** 7.3 ± 0.2 [10]* 7.7 ± 0.1 [7] 7.4 ± 0.2 [8] 7.3 ± 0.2 [8] 7.6 ± 0.1 [8]
Hematocrit M 0.4 ± 0 [10] 0.4 ± 0 [9] 0.4 ± 0 [10] 0.5 ± 0 [10]* 0.4 ± 0 [10] 0.4 ± 0 [10] 0.4 ± 0 [10] 0.4 ± 0 [8] 0.4 ± 0 [8] 0.4 ± 0 [8] 0.4 ± 0 [8]
F 0.4 ± 0 [10] 0.4 ± 0 [8]*** 0.4 ± 0 [10] 0.4 ± 0 [9] 0.4 ± 0 [10] 0.4 ± 0 [10]* 0.4 ± 0 [10]* 0.4 ± 0 [8] 0.4 ± 0 [8] 0.4 ± 0 [8] 0.4 ± 0 [8]
Mean corpuscular
hemoglobin [pg]
M 17.5 ± 0.2 [10] 18.5 ± 0.2 [9]** 18.4 ± 0.1 [10]** 18.4 ± 0.1 [10]*** 17.8 ± 0.1 [10] 17.7 ± 0.2 [10] 17.6 ± 0.1 [10] 17.5 ± 0.2 [8] 17.7 ± 0.2 [8] 17.8 ± 0.4 [8] 17.8 ± 0.2 [8]
F 18.4 ± 0.1 [10] 19.3 ± 0.2 [8]** 18.8 ± 0.2 [10] 19 ± 0.2 [9] 18.5 ± 0.2 [10] 18.9 ± 0.2 [10] 18.6 ± 0.2 [10] 18.6 ± 0.1 [7] 18.9 ± 0.1 [8] 18.6 ± 0.2 [8] 18.5 ± 0.1 [8]
Reticulocyte [%] M 3.2 ± 0.3 [10] 3.3 ± 0.3 [9] 3.9 ± 0.4 [10] 3.2 ± 0.2 [10] 3.3 ± 0.2 [10] 3.6 ± 0.3 [10] 3.8 ± 0.2 [10] 4 ± 0.4 [8] 5.8 ± 1.3 [8] 4.1 ± 0.2 [8] 3.8 ± 0.4 [8]
F 2.9 ± 0.3 [10] 3.7 ± 0.4 [8] 5 ± 0.5 [10]** 5.3 ± 0.5 [9]** 3.3 ± 0.4 [10] 3.8 ± 0.3 [10] 4.5 ± 0.8 [10] 3.6 ± 0.2 [7] 4 ± 0.2 [8] 4.1 ± 0.5 [8] 3.7 ± 0.4 [8]
White blood
cells
Lymphocyte [103/ml] M 5.5 ± 0.6 [10] 4.5 ± 0.5 [9] 4.2 ± 0.2 [10] 4.3 ± 0.3 [10] 5.6 ± 0.5 [10] 5.8 ± 0.6 [10] 4.3 ± 0.5 [10] 7.2 ± 0.6 [8] 6.8 ± 0.3 [8] 6.5 ± 1 [8] 7.6 ± 0.7 [8]
F 5.3 ± 0.7 [10] 3.7 ± 0.5 [8] 3.5 ± 0.3 [10]* 3.1 ± 0.3 [9]* 4.1 ± 0.3 [10] 4.2 ± 0.5 [10] 3.5 ± 0.3 [10]* 5.3 ± 0.6 [7] 5.1 ± 0.3 [8] 3.8 ± 0.3 [8] 5.8 ± 0.7 [8]
Monocyte [103/ml] M 0.4 ± 0 [10] 0.5 ± 0 [9]* 0.6 ± 0 [10]** 0.5 ± 0 [10] 0.4 ± 0 [10] 0.6 ± 0.1 [10] 0.5 ± 0.1 [10] 0.6 ± 0 [8] 0.5 ± 0.1 [8] 0.5 ± 0.1 [8] 0.5 ± 0.1 [8]
F 0.3 ± 0 [10] 0.5 ± 0.1 [8]* 0.4 ± 0 [10]* 0.5 ± 0.1 [9] 0.3 ± 0.1 [10] 0.4 ± 0 [10] 0.5 ± 0.1 [10] 0.4 ± 0 [7] 0.4 ± 0 [8] 0.3 ± 0.1 [8] 0.4 ± 0 [8]
Neutrophil [103/ml] M 1.4 ± 0.2 [10] 2.8 ± 0.4 [9]* 3 ± 0.5 [10]* 2.3 ± 0.3 [10]* 1.4 ± 0.2 [10] 2.2 ± 0.3 [10]* 2.9 ± 0.3 [10]** 1.6 ± 0.1 [8] 2.3 ± 0.4 [8] 1.8 ± 0.2 [8] 1.5 ± 0.2 [8]
F 1 ± 0.2 [10] 2.5 ± 0.3 [8]** 2.6 ± 0.5 [10]** 3.6 ± 1 [9]** 1.8 ± 0.4 [10]* 2.4 ± 0.3 [10]** 3.2 ± 0.6 [10]** 1 ± 0.1 [7] 1.1 ± 0.1 [8] 1 ± 0.1 [8] 0.8 ± 0.1 [8]
Results are presented as mean ± standard error. The sample size is in parenthesis. Difference from sham group at 90 d: signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Abbreviations: M, male; F, female; LM, lowmenthol; HM,
high menthol; R, recovery groups.
Table 4b
Statistically signiﬁcant differences for hematological parameters at the end of the 90-day and post-inhalation periods.
Parameter THS2.2M Medium vs.MRC(LM) THS2.2M High vs. MRC(HM). MRC (HM) vs. 3R4F Sham R vs.
Sham
3R4F R vs.
3R4F
MRC(HM) R vs.
MRC(HM)
THS2.2M
High R vs. THS2.2M High
Clotting potential Fibrinogen [s] M ¼ ¼ ¼ ¼ ¼ [*** ¼
F ¼ ¼ ¼ ¼ ¼ [*** [**
Fibrinogen [g/l] M ¼ ¼ ¼ ¼ ¼ Y** Y*
F ¼ ¼ ¼ ¼ Y* Y** Y*
Prothrombin time [s] M ¼ ¼ ¼ ¼ Y* Y*
F ¼ ¼ ¼ ¼ Y** ¼ Y**
Red blood cells Erythrocytes [106/ml] M ¼ Y** Y** ¼ ¼ ¼ Y**
F ¼ ¼ Y** Y* Y** ¼ ¼
Hematocrit l/l M ¼ Y*** [* ¼ Y** Y** ¼
F ¼ ¼ Y*** ¼ Y** Y* ¼
Mean corpuscular hemoglobin [pg] M Y** Y*** ¼ ¼ Y* ¼ ¼
F ¼ ¼ ¼ ¼ ¼ ¼ ¼
Reticulocytes [%] M ¼ ¼ ¼ ¼ ¼ [** ¼
F ¼ ¼ [* [* [** ¼ ¼
White blood cells Lymphocytes [103/ml] M [* ¼ ¼ ¼ [** [* [**
F ¼ ¼ ¼ ¼ [* ¼ [*
Monocytes [103/ml] M ¼ ¼ ¼ [** ¼ ¼ ¼
F ¼ ¼ ¼ ¼ ¼ ¼ ¼
Neutrophils [103/ml] M ¼ ¼ ¼ ¼ ¼ ¼ Y**
F ¼ ¼ ¼ ¼ Y** Y* Y**
Difference between groups: Signiﬁcance: *, p< 0.05; **p< 0.01; ***, p < 0.001. Symbols, Y indicates lower response in group 1 than in 2;[ indicates higher response in group 1 than in 2;¼ indicates no signiﬁcance. Abbreviations:
M, male; F, female; LM, low menthol; HM, high menthol; R, recovery groups.
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Table 5a
Organ weights relative to body weight determined at the end of the 90-day and post-inhalation periods.
Parameter [mg] 90 days 90 þ 42d
Sham 3R4F MRC(LM) MRC(HM) THS2.2M Low THS2.2M Medium THS2.2M High Sham R 3R4F R MRC(HM) R THS2.2M High R
Adrenal
gland (right)
M 0.6 ± 0.1 [10] 0.9 ± 0.1 [9]* 0.9 ± 0.1 [10]** 0.8 ± 0.1 [10] 0.8 ± 0 [10] 0.8 ± 0 [10]* 0.8 ± 0.1 [10] 0.4 ± 0 [8] 0.5 ± 0 [8] 0.5 ± 0.1 [8] 0.4 ± 0 [8]
F 1.3 ± 0.1 [10] 1.6 ± 0.1 [8]** 1.7 ± 0.1 [10]*** 1.7 ± 0.1 [9]*** 1.6 ± 0.1 [10]** 1.6 ± 0.1 [10]** 1.6 ± 0.1 [10]*** 0.9 ± 0.1 [7] 1 ± 0 [8] 1.1 ± 0.1 [8] 1 ± 0 [8]
Adrenal
gland (left)
M 0.7 ± 0 [10] 1 ± 0.1 [9]* 1 ± 0.1 [10]** 0.9 ± 0 [10]* 0.8 0 [10]* 0.8 ± 0 [10]** 0.9 ± 0 [10]*** 0.4 ± 0 [8] 0.4 ± 0 [8] 0.5 ± 0 [8] 0.4 ± 0 [8]
F 1.3 ± 0.1 [10] 1.8 ± 0.1 [8]*** 1.8 ± 0.1 [10]** 1.8 ± 0.1 [9]*** 1.7 ± 0.1 [10]** 1.8 ± 0.2 [10]** 1.7 ± 0.1 [10]*** 1 ± 0 [7] 1 ± 0 [8] 1.2 ± 0 [8] 1 ± 0.1 [8]
Brain M 51.4 ± 1.6 [10] 58.6 ± 1.1 [9]** 58.8 ± 1.6 [10]** 58 ± 1.9 [10]* 55.9 1.3 [10]* 54.3 1.5 [10] 55.2 ± 2.5 [10] 44.6 ± 1.3 [8] 45.9 ± 1.2 [8] 43.9 ± 1.6 [8] 41.3 ± 1.7 [8]
F 84.4 ± 1.4 [10] 76 ± 0.9 [8]*** 76.4 ± 2.2 [10]** 78.4 ± 1.4 [9]* 76.2 ± 1.7 [10]** 73.4 ± 1.9 [10]*** 72.8 ± 1.7 [10]*** 68.8 ± 3.1 [7] 67.3 ± 1.3 [8] 70.1 ± 1.9 [8] 67.4 ± 1.9 [8]
Heart M 31.1 ± 0.8 [10] 38.1 ± 1.2 [9]*** 38.7 ± 1 [10]*** 39.1 ± 1 [10]*** 33.4 ± 1.2 [10] 32.2 ± 0.5 [10] 35.4 ± 0.8 [10]*** 29.1 ± 0.8 [8] 29.9 ± 0.6 [8] 29.5 ± 0.5 [8] 28.9 ± 1.2 [8]
F 36.5 ± 1.3 [10] 43.1 ± 1 [8]*** 42.8 ± 1.5 [10]** 43.1 ± 1.8 [9]** 36.2 ± 0.9 [10] 40.4 ± 1.7 [10]* 38.3 ± 0.9 [10] 32.1 ± 0.9 [7] 33 ± 0.9 [8] 33.4 ± 0.6 [8] 34.1 ± 1.5 [8]
Kidney (right) M 28.9 ± 0.9 [10] 33.7 ± 0.5 [9]*** 32.8 ± 0.8 [10]** 33.4 ± 0.7 [10]** 32 ± 0.9 [10]* 30.7 ± 0.9 [10] 33 ± 1.1 [10]** 28.2 ± 0.6 [8] 29 ± 1.2 [8] 30.1 ± 1.1 [8] 27.6 ± 0.9 [8]
F 33.2 ± 0.8 [10] 33.6 ± 0.6 [8] 33.9 ± 0.8 [10] 32.9 ± 0.9 [9] 33.2 ± 0.7 [10] 33.6 ± 0.6 [10] 33.6 ± 1.3 [10] 29.5 ± 1.2 [7] 30.4 ± 0.6 [8] 30.6 ± 1 [8] 30.3 ± 0.8 [8]
Kidney (left) M 28.8 ± 0.9 [10] 32.8 ± 0.6 [9]** 32 ± 0.8 [10]* 32.3 ± 0.8 [10]** 31.3 ± 0.7 [10]* 30.4 ± 0.8 [10] 32.4 ± 1 [10]* 27.6 ± 0.7 [8] 28.4 ± 1.1 [8] 30.3 ± 0.9 [8] 28.1 ± 1.3 [8]
F 31.7 ± 0.7 [10] 32.5 ± 0.5 [8] 32.8 ± 0.8 [10] 32.5 ± 0.8 [9] 32.8 ± 0.7 [10] 32.6 ± 0.6 [10] 32.3 ± 1.2 [10] 28.4 ± 1 [7] 28.6 ± 0.7 [8] 29.8 ± 0.5 [8] 29.8 ± 0.9 [8]
Liver M 330 ± 10.8 [10] 379.7 ± 13.6 [9]* 373.2 ± 13.5 [10]* 379.8 ± 10.9 [10]** 351.3 ± 7.5 [10] 362.3 ± 5.6 [10]* 412 ± 12.6 [10]*** 330.3 ± 4.3 [8] 331 ± 4.8 [8] 339.3 ± 8 [8] 342.9 ± 11.7 [8]
F 357.4 ± 9.1 [10] 416.4 ± 7.6 [8]*** 409.5 ± 7 [10]*** 415.6 ± 13.5 [9]** 406.5 ± 11.8 [10]** 415.3 ± 7.3 [10]*** 425.4 ± 10.9 [10]*** 332.6 ± 12.8 [7] 344.7 ± 5.3 [8] 344.4 ± 9.8 [8] 328.1 ± 7.8 [8]
Lung, Larynx,
Trachea
M 36.8 ± 0.8 [10] 56.9 ± 1.8 [9]*** 57.2 ± 1.8 [10]*** 54.5 ± 1.5 [10]*** 39.6 ± 1 [10]* 39.5 ± 0.9 [10]* 42.1 ± 1.4 [10]** 33.8 ± 0.7 [8] 39.6 ± 1.2 [8] 38.4 ± 0.9 [8] 33.7 ± 1.1 [8]
F 52.4 ± 0.9 [10] 64.3 ± 1.5 [8]*** 67.3 ± 2.5 [10]*** 68.8 ± 3.1 [9]*** 49.4 ± 1.3 [10] 48.9 ± 1.1 [10]* 49.8 ± 0.6 [10]* 45.4 ± 2.3 [8] 54.5 ± 2.4 [8] 54.1 ± 2.5 [8] 46.4 ± 0.7 [8]
Ovary (right) F 1.4 ± 0.1 [10] 2 ± 0.3 [8]* 1.7 ± 0.2 [10] 1.7 ± 0.1 [9] 2 ± 0.1 [10]** 2.1 ± 0.1 [10]** 1.5 ± 0.1 [10] 1.5 ± 0.1 [7] 1.6 ± 0.1 [8] 1.6 ± 0.2 [8] 1.6 ± 0.1 [8]
Ovary (left) F 1.4 ± 0.1 [10] 2.1 ± 0.4 [8] 1.7 ± 0.1 [10]* 1.5 ± 0.2 [9] 1.8 ± 0.1 [10]** 1.8 ± 0.1 [10]* 1.5 ± 0.1 [10] 1.3 ± 0.1 [7] 1.5 ± 0.1 [8] 1.5 ± 0.2 [8] 1.4 ± 0.1 [8]
Spleen M 17.5 ± 0.5 [10] 16.2 ± 0.7 [9] 17 ± 0.7 [10] 15.8 ± 0.7 [10] 16.9 ± 0.5 [10] 17.1 ± 0.5 [10] 14.3 ± 0.8 [10]** 17.9 ± 1.1 [8] 18.9 ± 1.1 [8] 17.4 ± 0.7 [8] 16.7 ± 1.1 [8]
F 20.8 ± 0.9 [10] 16 ± 0.4 [8]*** 19.3 ± 0.9 [10] 19.1 ± 1.1 [9] 19.4 ± 0.7 [10] 18.5 ± 0.4 [10]* 18.8 ± 1.2 [10] 21.1 ± 1.1[7] 21.2 ± 1.1 [8] 21.2 ± 0.5 [8] 20.6 ± 0.6 [8]
Testes (right) M 35.2 ± 2.9 [10] 48.7 ± 1.4 [9]** 48 ± 1.2 [10]*** 49.9 ± 2.3 [10]** 36.2 ± 3 [10] 36.5 ± 2.5 [10] 46.6 ± 1.6 [10]** 33.2 ± 1.8[8] 37.7 ± 1.1 [8] 39.2 ± 0.9 [8] 35.9 ± 1.1 [8]
Testes (left) M 34.4 ± 3.3 [10] 48.6 ± 1.5 [9]** 44.2 ± 2.7 [10]* 45.6 ± 2.8 [10]* 35.5 ± 2.5 [10] 35.7 ± 1.7 [10] 46.3 ± 1.4 [10]** 34.1 ± 1.5[8] 37.2 ± 1 [8] 39.1 ± 1 [8] 34.8 ± 1.2 [8]
Thymus M 4.9 ± 0.3 [10] 2.6 ± 0.2 [9]*** 3 ± 0.4 [10]*** 2.7 ± 0.2 [10]*** 3.5 ± 0.4 [10]** 3.3 ± 0.3 [10]*** 2.7 ± 0.2 [10]*** 3.8 ± 0.3[8] 4.5 ± 0.3 [8] 4.5 ± 0.2 [8] 4.1 ± 0.4 [8]
F 7.2 ± 0.4 [10] 3.7 ± 0.4 [8]*** 3.6 ± 0.3 [10]*** 3.9 ± 0.3 [9]*** 5.4 ± 0.5 [10]** 3.9 ± 0.5 [10]*** 4.2 ± 0.5 [10]*** 5.9 ± 0.7[7] 8.3 ± 0.7 [8] 7.4 ± 0.8 [8] 8.1 ± 0.9 [8]
Uterus F 29.1 ± 4.2 [10] 18.4 ± 2.2 [8]* 17.4 ± 1.9 [10]*** 12.8 ± 1 [9]* 16.7 ± 1.4 [10]** 22.5 ± 5 [10]* 12.8 ± 0.8 [10]*** 24 ± 3[7] 23.2 ± 2.2 [8] 21.5 ± 2.3 [8] 24 ± 4.3 [8]
Results are presented as mean ± standard error. The sample size is in parentheses. Difference from sham group at 90d: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Abbreviations: M, male; F, female; LM, lowmenthol; HM,
high menthol; R, recovery groups.
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Table 5b
Statistically signiﬁcant differences for organ weights relative to body weight at the end of the 90-day and post-inhalation periods.
Parameter THS2.2M
Medium vs. MRC(LM)
THS2.2M
High vs. MRC(HM).
MRC (HM) vs.
3R4F
Sham R vs.
Sham
3R4F R vs. 3R4F MRC(HM) R vs.
MRC(HM)
THS2.2M High R vs.
THS2.2M High
Adrenal gland (right) M ¼ ¼ ¼ Y** Y*** Y*** Y***
F ¼ ¼ ¼ Y** Y*** Y*** Y***
Adrenal gland (left) M ¼ ¼ ¼ Y*** Y** Y*** Y***
F ¼ ¼ ¼ Y*** Y*** Y*** Y***
Brain M ¼ ¼ ¼ Y** Y*** Y*** Y***
F ¼ Y* ¼ Y** Y*** Y** ¼
Heart M Y*** Y** ¼ ¼ Y*** Y*** Y***
F ¼ Y* ¼ Y* Y*** Y*** Y*
Kidney (right) M ¼ ¼ ¼ ¼ Y** Y* Y**
F ¼ ¼ ¼ Y* Y** ¼ Y*
Kidney (left) M ¼ ¼ ¼ ¼ Y** ¼ Y*
F ¼ ¼ ¼ Y* Y*** Y* ¼
Liver M ¼ ¼ ¼ ¼ Y** Y** Y***
F ¼ ¼ ¼ ¼ Y*** Y*** Y***
Lung M Y*** Y*** ¼ Y** Y*** Y*** Y***
F Y*** Y*** ¼ Y* Y** Y** Y**
Ovary (right) F ¼ ¼ ¼ ¼ ¼ ¼ ¼
Ovary (left) F ¼ ¼ ¼ ¼ ¼ ¼ ¼
Spleen M ¼ ¼ ¼ ¼ ¼ ¼ ¼
F ¼ ¼ [* ¼ [** ¼ ¼
Testes (right) M Y** ¼ ¼ ¼ Y*** Y** Y***
Testes (left) M Y* ¼ ¼ ¼ Y*** ¼ Y***
Thymus M ¼ ¼ ¼ Y* [*** [*** [**
F ¼ ¼ ¼ ¼ [*** [** [**
Uterus F ¼ ¼ Y* ¼ ¼ Y** Y**
Difference between groups: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Symbols, Y indicates lower response in group 1 than in 2; [ indicates higher response in group 1
than in 2; ¼ indicates no signiﬁcance. Abbreviations: M, male; F, female; LM, low menthol; HM, high menthol; R, recovery groups.
A. Oviedo et al. / Regulatory Toxicology and Pharmacology 81 (2016) S93eS122S106At the end of the 42-day post-inhalation recovery period, the
effects of theMRC and 3R4F exposure onmost upregulated analytes
at the end of the exposure period were reduced, but still higher
than in the sham group (Fig. 2), showing consistency with the BALF
cell count results.
3.6. Gross pathology
Type, incidence, and severity of the macroscopical observations
were not regarded as treatment-related. No signiﬁcant exposure-
related effects were observed (data not shown).
3.7. Histopathology of non-respiratory tract organs
The histopathological examination of THS2.2M MA- and MRC
MS-exposed animals conﬁrmed exposure-related effects for single
endpoints in non-respiratory tract organs, and are regarded as
normal within this type of study. These changes included vacuoli-
zation of hepatocytes (MRC(HM) and THS2.2M High female groups
only) and thymus atrophy, as seen in previous studies (Phillips
et al., 2015a; Wong et al., 2016 (in this issue)).
3.8. Histopathology of respiratory tract organs
To investigate the morphological effects on respiratory tract
organs after exposure to MRC MS and THS2.2M MA, a semi-
quantitative histopathological assessment was performed for the
nose, larynx, trachea/bifurcation, and left lung.
Histopathological scores and incidences are given in Tables 7a
and 7b only for those endpoints that were statistically signiﬁcantly
different from sham-exposed rats.
3.8.1. Nose
At the end of the 90-day inhalation period, histological changes
observed in the nasal epithelia for both male and female rats of the
MRC groups included goblet-cell hyperplasia or squamousmetaplasia accompanied by the loss of goblet cells along the nasal
septum and dorsal meatus, basal cell hyperplasia and/or squamous
metaplasia of the respiratory epithelium along the lateral walls,
olfactory epithelial cell atrophy and loss of nerve bundles, squa-
mous cell metaplasia of the olfactory epithelium, and degeneration
of the glomerular layers in the olfactory bulb. The ﬁndings observed
in MRC(LM) and MRC(HM) groups were of similar severity and
incidence, and had high severity scores in nose level 1 and mod-
erate to high severity scores in nose levels 3 and 4. The incidence
and/or mean severity was higher in females compared with males
across all groups; however, the overall trend of the ﬁndings
remained the same. No differences were observed in the nasal
passages of MRC-exposed groups in any of the histopathological
endpoints compared with the 3R4F group. Furthermore, the pres-
ence of menthol in MS did not introduce any novel effect, nor did it
alter the severity and/or incidence of histopathological ﬁndings
observed from 3R4F MS exposure alone.
Changes observed in the THS2.2M High group were moderate at
nose level 1 and lower than in MRC-exposed rats, and moderate or
absent in nose levels 3 and 4.
With the exception of the changes seen at the nasal septum, all
ﬁndings diagnosed in the THS2.2 Low and THS2.2 Medium groups
were considered incidental. In the THS2.2M exposure groups, there
was a concentration-dependent increase in severity and/or inci-
dence of basal cell hyperplasia, and goblet cell loss at the nasal
septum.
Following the 42-day post-inhalation recovery period, the
number of goblet cells in the anterior nasal septumwas statistically
signiﬁcantly higher in THS2.2M High group and MRC MS-exposed
groups compared with sham. Proliferation and hypertrophy of
goblet cells in the nasal septum were observed in parallel with the
loss of goblet cells.3.8.2. Larynx
In the larynx, severity and incidence of hyperplasia of the
squamous epithelium at the base of the epiglottis, lower and upper
Table 6a
Statistically signiﬁcant differences in differential cell counts in BALF at the end of the 90-day and post-inhalation periods.
Parameter 90 days 90 þ 42d
Sham 3R4F MRC(LM) MRC(HM) THS2.2M Low THS2.2M Medium THS2.2M High Sham R 3R4F R MRC(HM) R THS2.2M High R
Total cells (105) M 40 ± 3.5 [10] 227.8 ± 17.9 [9]* 210.7 ± 30.4 [10]** 164.7 ± 13.1 [10] 43.2 ± 5.3 [10] 36.7 ± 3.7 [10]* 48 ± 5.5 [10] 40 ± 4.6 [8] 68.3 ± 14.7 [8] 59.7 ± 9.4 [8] 37.6 ± 4.9 [8]
F 25.2 ± 3.7 [10] 138.1 ± 12.4 [8]** 193.3 ± 42.1 [10]*** 147.7 ± 19.5 [9]*** 37.3 ± 4.5 [10]** 31.9 ± 4.2 [10]** 32.9 ± 3.4 [10]*** 19 ± 4.7 [7] 50.1 ± 7.4 [8] 69.6 ± 8.1 [8] 19.4 ± 3 [8]
Eosinophils (105) M 0 ± 0 [10] 0.3 ± 0 [9]* 0.4 ± 0.1 [10]** 0.3 ± 0.1 [10]* 0.1 0.1 [10]* 0 ± 0 [10]** 0 ± 0 [10]*** 0 ± 0 [8] 0.1 ± 0 [8] 0.1 ± 0 [8] 0 ± 0 [8]
F 0 ± 0 [10] 0.3 ± 0.1 [8]*** 0.6 ± 0.2 [10]** 0.4 ± 0.1 [9]*** 0 ± 0 [10]** 0 ± 0 [10]** 0 ± 0 [10]*** 0 ± 0 [7] 0.1 ± 0 [8] 0.2 ± 0.1 [8] 0 ± 0 [8]
Lymphocytes (105) M 0.4 ± 0.1 [10] 4.6 ± 0.5 [9]** 6.6 ± 1.9 [10]** 3.5 ± 0.5 [10]* 0.3 0.1 [10]* 0.3 0.1 [10] 0.3 ± 0.1 [10] 0.5 ± 0.1 [8] 4.7 ± 1.4 [8] 3.6 ± 0.9 [8] 0.7 ± 0.2 [8]
F 0.2 ± 0 [10] 4.1 ± 0.9 [8]*** 4.6 ± 1.3 [10]** 3.9 ± 0.9 [9]* 0.1 ± 0 [10]** 0.1 ± 0 [10]*** 0.2 ± 0.1 [10]*** 0.3 ± 0.1 [7] 4.1 ± 1.2 [8] 4 ± 0.7 [8] 0.2 ± 0 [8]
Macrophages (105) M 39.2 ± 3.4 [10] 135.9 ± 10.7 [9]*** 110.9 ± 15.1 [10]*** 100.1 ± 10.2 [10]*** 39.8 ± 3 [10] 36 ± 3.7 [10] 47.1 ± 5.5 [10]*** 39.2 ± 4.6 [8] 50.1 ± 12.4 [8] 42.6 ± 6.8 [8] 36.5 ± 4.8 [8]
F 24.8 ± 3.7 [10] 64.7 ± 6.4 [8]*** 104.4 ± 25.7 [10]** 77.7 ± 10.8 [9]** 36.8 ± 4.4 [10] 31.5 ± 4.2 [10]* 32.3 ± 3.5 [10] 18.5 ± 4.6 [7] 35.5 ± 5.8 [8] 48.9 ± 5.4 [8] 19.2 ± 3 [8]
Neutrophils (105) M 0.3 ± 0.1 [10] 87 ± 9.8 [9]*** 92.8 ± 18.7 [10]** 60.7 ± 7.2 [10]** 3 ± 2.4 [10]* 0.3 ± 0.1 [10] 0.6 ± 0.1 [10]** 0.2 ± 0.1 [8] 13.5 ± 3.7 [8] 13.4 ± 2 [8] 0.4 ± 0.1 [8]
F 0.1 ± 0 [10] 69 ± 5.7 [8] 83.7 ± 16.5 [10] 65.7 ± 10 [9] 0.3 ± 0.1 [10] 0.3 ± 0.1 [10] 0.5 ± 0.1 [10] 0.1 ± 0 [7] 10.3 ± 3 [8] 16.6 ± 2.6 [8] 0.1 ± 0 [8]
Results are presented as mean ± standard error. The sample size is in parentheses. Difference from sham group at 90d: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Abbreviations: M, male; F, female; LM, lowmenthol; HM,
high menthol; R, recovery groups.
Table 6b
Statistically signiﬁcant differences in differential cell counts in BALF at the end of the 90-day and post-inhalation periods.
Parameter THS2.2M Medium vs. MRC(LM) THS2.2M High vs. MRC(HM). MRC (HM) vs. 3R4F Sham R vs. Sham 3R4F R vs. 3R4F MRC(HM) R vs. MRC(HM) THS2.2M High R vs. THS2.2M High
Total cells (105) M Y*** Y*** Y* ¼ Y*** Y** Y***
F Y** Y*** ¼ ¼ Y*** Y** Y**
Eosinophils (105) M Y*** Y*** ¼ ¼ Y*** Y* ¼
F Y*** Y*** ¼ ¼ Y** ¼ ¼
Lymphocytes (105) M Y*** Y*** ¼ ¼ ¼ ¼ ¼
F Y*** Y*** ¼ ¼ ¼ ¼ ¼
Macrophages (105) M Y*** Y*** Y* ¼ Y*** Y*** ¼
F Y* Y** ¼ ¼ Y** Y* Y*
Neutrophils (105) M Y*** Y*** Y* ¼ Y*** Y*** ¼
F Y*** Y*** ¼ ¼ Y*** Y** Y***
Difference between groups: Signiﬁcance: *, p < 0.05; **p< 0.01; ***, p < 0.001. Symbols, Y indicates lower response in group 1 than in 2; [ indicates higher response in group 1 than in 2;¼ indicates no signiﬁcance. Abbreviations:
M, male; F, female; LM, low menthol; HM, high menthol; R, recovery groups.
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Fig. 2. Analysis of selected cytokines and chemokines in bronchoalveolar lavage ﬂuid (BALF). Abbreviations: M, male; F, female; LM, low menthol; HM, high menthol.
A. Oviedo et al. / Regulatory Toxicology and Pharmacology 81 (2016) S93eS122S108arytenoid projections, ventral pouch, and vocal folds in the mid-
lateral region were statistically signiﬁcantly higher in all exposed
groups compared with sham. However, severity and incidence
were statistically signiﬁcantly lower in THS2.2M MA-exposed
groups compared with MRC MS-exposed groups, which showed a
fully developed hyperkeratotic squamous metaplasia.
Larynx morphometry revealed that mean laryngeal epithelial
thickness at the base of the epiglottis, lateral ﬂoor, and the aryte-
noid projections was statistically signiﬁcantly higher in MRC MS-exposed groups (Tables 8a and 8b). There was also a
concentration-dependent increase observed in the THS2.2M MA-
exposed groups which was statistically signiﬁcantly lower
compared with MRC groups.
Following the 42-day post-inhalation recovery period, all effects
observed in the larynx were completely reversed in THS2.2M MA-
exposed groups, and partially reversed in MRC groups.
No differences were observable in the larynx of MRC-exposed
groups compared with the 3R4F group. Furthermore, the
Table 7a
Statistically signiﬁcant differences in histopathological ﬁndings in the respiratory tract at the end of the 90-day and post-inhalation periods.
Parameter 90d 90 þ 42d
Sham 3R4F MRC(LM) MRC(HM) THS2.2M Low THS2.2M Medium THS2.2M High Sham R 3R4F R MRC(HM) R THS2.2M High R
NosedLevel 1
Nasal Septum - Respiratory Epithelium
Basal cell
hyperplasia
M 0.1 ± 0.1 [1/10] 2.7 ± 0.2 [9/9]*** 1.8 ± 0.4 [8/10]** 1.5 ± 0.3 [8/10]** 0.5 ± 0.2 [4/10] 0.7 ± 0.2 [7/10]** 2.1 ± 0.4 [5/10]*** 0 ± 0 [0/8] 0.3 ± 0.2 [2/8] 0.3 ± 0.16 [2/8] 0.4 ± 0.18 [3/8]
F 0 ± 0 [0/10] 1 ± 0.3 [5/8]** 2.4 ± 0.5 [7/8]*** 1.3 ± 0.5 [5/9]** 0.3 ± 0.2 [3/10] 0.6 ± 0.16 [6/10]*** 1.7 ± 0.4 [8/10]*** 0 ± 0 [0/8] 0.1 ± 0.13 [1/8] 0.3 ± 0.25 [1/8] 0.1 ± 0.13 [1/8]
Goblet cell
hyperplasia/
hypertrophy
M 0.9 ± 0.28 [6/10] 2.1 ± 0.35 [9/9]* 0.4 ± 0.16 [4/10] 1.1 ± 0.38 [6/10] 0.6 ± 0.31 [3/10] 0.9 ± 0.23 [7/10] 0.5 ± 0.22 [4/10] 0.3 ± 0.16 [2/8] 4.3 ± 0.25 [8/8] 4 ± 0.42 [8/8] 2.3 ± 0.49 [7/8]
F 0 ± 0 [0/10] 0.5 ± 0.27 [6/8]* 1 ± 0.3 [6/10]** 0.7 ± 0.24 [5/9]** 0.6 ± 0.22 [5/10]* 1.3 ± 0.4 [6/10]*** 0.1 ± 0.1 [1/10] 0.1 ± 0.13 [1/8] 4.1 ± 0.4 [8/8] 2.9 ± 0.44 [8/8] 2 ± 0.57 [8/8]
Goblet cell loss M 0.3 ± 0.15 [3/10] 3.9 ± 0.2 [9/9]*** 4.8 ± 0.13 [10/10]*** 4.3 ± 0.21 [10/10]*** 0.8 ± 0.25 [6/10] 1.2 ± 0.29 [8/10]* 3.9 ± 0.18 [10/10]*** 0.3 ± 0.16 [2/8] 1.8 ± 0.41 [8/8] 1.3 ± 0.25 [7/8]** 0.9 ± 0.4 [4/8]
F 0.7 ± 0.26 [5/10] 4.3 ± 0.25 [8/8]*** 4.4 ± 0.22 [10/10]*** 4.6 ± 0.18 [9/9]*** 1.3 ± 0.3 [8/10] 1.2 ± 0.33 [7/10] 4.1 ± 0.23 [10/10]*** 0.4 ± 0.18 [3/8] 1.9 ± 0.52 [7/8]* 2.1 ± 0.52 [6/8]* 1.3 ± 0.37 [6/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 2.6 ± 0.24 [9/9]*** 2 ± 0.3 [9/10]*** 2.2 ± 0.39 [9/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.9 ± 0.43 [4/10]* 0 ± 0 [0/8] 0.3 ± 0.25 [1/8] 0.3 ± 0.25 [1/8] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 3.5 ± 0.19 [8/8]*** 3.5 ± 0.27 [10/8]*** 3.6 ± 0.34 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 1.6 ± 0.4 [7/10]*** 0 ± 0 [0/8] 0.4 ± 0.26 [2/8] 1 ± 0.57 [3/8] 0.4 ± 0.38 [1/8]
Lateral WalldRespiratory Epithelium
Basal cell
hyperplasia
M 0.1 ± 0.1 [1/10] 1.6 ± 0.24 [8/9]*** 0.5 ± 0.22 [4/10] 0.9 ± 0.23 [7/10]*** 0.1 ± 0.1 [1/10] 0.5 ± 0.17 [5/10] 1.1 ± 0.23 [8/10]** 0.1 ± 0.13 [1/8] 1 ± 0.27 [6/8] 0.4 ± 0.18 [3/8] 0.4 ± 0.18 [3/8]
F 0 ± 0 [0/10] 0.9 ± 0.35 [4/8]* 0.4 ± 0.22 [3/10] 0.6 ± 0.24 [4/9]* 0.1 ± 0.1 [1/10] 0.3 ± 0.15 [3/10] 0.2 ± 0.13 [2/10] 0.1 ± 0.13 [1/8] 0.5 ± 0.27 [5/8] 0 ± 0 [0/8] 0.1 ± 0.13 [1/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 3.1 ± 0.35 [9/9]*** 3.6 ± 0.16 [10/10]*** 3.7 ± 0.21 [10/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 1.9 ± 0.55 [7/10]** 0 ± 0 [0/8] 1.6 ± 0.32 [7/8] 3.3 ± 0.31 [8/8] 1.5 ± 0.57 [5/8]
F 0 ± 0 [0/10] 3.4 ± 0.32 [8/8]*** 3.6 ± 0.31 [10/10]*** 4 ± 0.24 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 3.7 ± 0.15 [10/10]*** 0 ± 0 [0/8] 2.9 ± 0.48 [7/8] 3.5 ± 0.38 [8/8] 2.9 ± 0.52 [7/8]
MaxilloturbinatedRespiratory Epithelium
Basal cell
hyperplasia
M 0.2 ± 0.2 [1/10] 0.2 ± 0.22 [1/9] 0.8 ± 0.42 [3/10] 0.5 ± 0.22 [4/10] 0.2 ± 0.13 [2/10] 0.9 ± 0.23 [7/10]* 0.7 ± 0.26 [5/10] 0 ± 0 [0/8] 1.3 ± 0.16 [8/8] 1 ± 0.19 [7/8] 0.5 ± 0.19 [4/8]
F 0 ± 0 [0/10] 0 ± 0 [0/8] 0 ± 0 [0/10] 0.2 ± 0.15 [7/9] 0.3 ± 0.15 [3/10] 0.4 ± 0.16 [4/10]* 0.1 ± 0.1 [1/10] 0 ± 0 [0/8] 0.8 ± 0.31 [4/8] 0 ± 0 [0/8] 0.4 ± 0.26 [2/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 4 ± 0 [9/9]*** 3.6 ± 0.22 [10/10]*** 3.5 ± 0.22 [10/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 1.4 ± 0.43 [7/10]** 0 ± 0 [0/8] 1.5 ± 0.19 [8/8] 1.5 ± 0.27 [6/8] 0.6 ± 0.32 [3/8]
F 0 ± 0 [0/10] 4.1 ± 0.13 [8/8]*** 4.4 ± 0.16 [10/10]*** 3.9 ± 0.2 [10/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 3.1 ± 0.43 [10/10]*** 0 ± 0 [0/8] 2 ± 0.33 [7/8] 2.1 ± 0.52 [5/8] 0.6 ± 0.26 [4/8]
NasoturbinatedRespiratory Epithelium
Basal cell
hyperplasia
M 0.1 ± 0.1 [1/10] 0.8 ± 0.36 [4/9] 0.7 ± 0.21 [4/10]* 0.4 ± 0.27 [8/10] 0.2 ± 0.13 [2/10] 0.6 ± 0.16 [6/10]* 0.6 ± 0.27 [4/10] 0 ± 0 [0/8] 0.9 ± 0.13 [7/8] 0.5 ± 0.19 [4/8] 0.5 ± 0.19 [4/8]
F 0 ± 0 [0/10] 0.3 ± 0.25 [1/8] 0 ± 0 [0/10] 0.1 ± 0.11 [8/9] 0.3 ± 0.15 [3/10] 0.4 ± 0.16 [4/10]* 0.3 ± 0.15 [3/10] 0.4 ± 0.18 [3/8] 0.9 ± 0.35 [5/8] 0.1 ± 0.13 [1/8] 0.4 ± 0.18 [3/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 3 ± 0.29 [9/9]*** 2.9 ± 0.31 [10/10]*** 3.1 ± 0.23 [10/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 1.6 ± 0.45 [7/10]** 0 ± 0 [0/8] 1.9 ± 0.3 [7/8] 2.6 ± 0.32 [8/8] 0.6 ± 0.38 [3/8]
F 0 ± 0 [0/10] 3.5 ± 0.38 [8/8]*** 3.7 ± 0.15 [10/10]*** 4.1 ± 0.26 [10/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 2.4 ± 0.34 [10/10]*** 0.5 ± 0.5 [1/8] 2.5 ± 0.38 [8/8] 3 ± 0.46 [7/8] 0.4 ± 0.18 [3/8]
Dorsal MeatusdRespiratory Epithelium
Squamous cell
metaplasia
M 0 ± 0 [0/10] 3 ± 0.24 [9/9]*** 3 ± 0.26 [10/10]*** 2 ± 0.54 [7/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.5 ± 0.22 [4/10]* 0 ± 0 [0/8] 0.1 ± 0.13 [1/8] 0 ± 0 [8/8] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 3.4 ± 0.38 [8/8]*** 3.2 ± 0.33 [10/10]*** 3.4 ± 0.38 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 1 ± 0.42 [5/10]* 0 ± 0 [0/8] 0.4 ± 0.38 [1/8] 0.3 ± 0.25 [7/8] 0 ± 0 [0/8]
Submucosa/Lamina Propria
Inﬁltrate, mixed
cells
(incidence)
M 0 ± 0 [0/10] 1 ± 0 [9/9]*** 1.0 ± 0 [10]*** 1 ± 0.1 [10/10]*** 0.1 ± 0 [1/10] 0.1 ± 0.1 [1/10] 0.6 ± 0.2 [4/10] * 0 ± 0 [0/8] 1 ± 0 1 ± 0 0.9 ± 0.1 [8/8]
[8/8] [8/8]
F 0 ± 0 [0/10] 1 ± 0 [8/8]*** 1.0 ± 0 [10]*** 1 ± 0 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.8 ± 0.1 [2/10] *** ±0 [0/8] 1 ± 0 1 ± 0 0.8 ± 0.2 [8/8]
[8/8] [8]/8
Nasal CavitydLumen
Necrotic cellular
debris
M 0 ± 0 [0/10] 1 ± 0 [9/9]*** 0.8 ± 0.13 [8/10]*** 0.8 ± 0.13 [8/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.5 ± 0.17 [5/10]* 0 ± 0 [0/8] 0.6 ± 0.18 [5/8] 0.5 ± 0.19 [4/8] 0.1 ± 0.13 [1/8]
F 0 ± 0 [0/10] 0.8 ± 0.16 [6/8]*** 0.7 ± 0.15 [7/10]*** 0.9 ± 0.11 [8/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.4 ± 0.16 [6/10] 0 ± 0 [0/8] 0.4 ± 0.18 [3/8] 0.5 ± 0.19 [4/8] 0 ± 0 [0/8]
Amorphous
eosinophilic
material
M 0 ± 0 [0/10] 0.9 ± 0.11 [8/9]*** 1 ± 0 [10/10]*** 0.8 ± 0.13 [8/10]*** 0 ± 0 [0/10] 0.1 ± 0.1 [1/10] 0.6 ± 0.16 [6/10]* 0 ± 0 [0/8] 0.5 ± 0.19 [4/8] 0.5 ± 0.19 [4/8] 0.3 ± 0.16 [2/8]
F 0 ± 0 [0/10] 0.9 ± 0.13 [7/8]*** 0.8 ± 0.13 [8/10]*** 1 ± 0 [9/9]*** 0 ± 0 [0/10] 0.1 ± 0.1 [1/10] 0.5 ± 0.17 [5/10]* 0 ± 0 [0/8] 0.4 ± 0.18 [3/8] 0.4 ± 0.18 [3/8] 0 ± 0 [0/8]
NosedLevel 2
Dorsal MeatusdOlfactory Epithelium
Atrophy/loss M 0 ± 0 [0/10] 4 ± 0.24 [9/9]*** 3.5 ± 0.22 [10/10]*** 4 ± 0.15 [10/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.5 ± 0.22 [4/10]* 0 ± 0 [0/8] 3.6 ± 0.26 [8/8] 2.6 ± 0.3 [8/7] 0.4 ± 0.26 [2/8]
F 0 ± 0 [0/10] 3.8 ± 0.16 [8/8]*** 4 ± 0.21 [10/10]*** 3.9 ± 0.35 [8/8]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 1.1 ± 0.28 [7/10]** 0 ± 0 [0/8] 3.5 ± 0.27 [8/8] 3.5 ± 0.27 [8/8] 0.5 ± 0.19 [4/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 2.2 ± 0.36 [9/9]*** 2.1 ± 0.38 [10/10]*** 2 ± 0.3 [10/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 1.3 ± 0.16 [8/8] 1.1 ± 0.14 [8/7] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 2.4 ± 0.42 [8/8]*** 2.7 ± 0.4 [10/10]*** 2.1 ± 0.61 [7/8]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 1.1 ± 0.3 [6/8] 1.4 ± 0.26 [7/8] 0 ± 0 [0/8]
NasoturbinatedRespiratory Epithelium
Basal cell
hyperplasia
M 0 ± 0 [0/10] 2.3 ± 0.17 [9/9]*** 2.4 ± 0.31 [10/10]*** 2.7 ± 0.21 [10/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.1 ± 0.1 [1/10] 0 ± 0 [0/8] 0.5 ± 0.19 [4/8] 0.9 ± 0.23 [6/8] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 2 ± 0.33 [7/8]*** 2.1 ± 0.28 [10/10]*** 2.6 ± 0.56 [7/8]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.8 ± 0.2 [7/10]** 0 ± 0 [0/8] 0.4 ± 0.18 [5/8] 0.1 ± 0.13 [7/8] 0 ± 0 [0/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 0.6 ± 0.24 [4/9]* 1.5 ± 0.37 [9/10]*** 1 ± 0.3 [6/10]** 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 0.1 ± 0.13 [7/8] 0 ± 0 [0/8] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 1.3 ± 0.31 [6/8]** 1.1 ± 0.28 [7/10]** 1.1 ± 0.3 [6/8]** 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 0.1 ± 0.13 [7/8] 0 ± 0 [0/8] 0 ± 0 [0/8]
Submucosa/Lamina Propria
Loss of nerve
bundlesd
dorsal meatus
M 0 ± 0 [0/10] 4.4 ± 0.18 [9/9]*** 4 ± 0.21 [10/10]*** 4.3 ± 0.21 [10/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.6 ± 0.27 [4/10]* 0 ± 0 [0/7] 3 ± 0.46 [8/8] 2.7 ± 0.36 [8/7] 0.4 ± 0.2 [4/7]
F 0 ± 0 [0/10] 4.4 ± 0.18 [8/8]*** 4 ± 0.21 [10/10]*** 4.4 ± 0.18 [8/8]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.8 ± 0.22 [6/9]** 0 ± 0 [0/8] 2.9 ± 0.35 [8/8] 3.6 ± 0.26 [8/8] 0.5 ± 0.19 [4/8]
M 0 ± 0 [0/10] 1 ± 0 [9/9]*** 1 ± 0 [10/10]*** 1 ± 0 [10/10]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 1 ± 0 [8/8] 1 ± 0 [8/8] 0 ± 0 [0/8]
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Table 7a (continued )
Parameter 90d 90 þ 42d
Sham 3R4F MRC(LM) MRC(HM) THS2.2M Low THS2.2M Medium THS2.2M High Sham R 3R4F R MRC(HM) R THS2.2M High R
Inﬁltrate, mixed
cell
F 0 ± 0 [0/10] 1 ± 0 [8/8]*** 1 ± 0 [10/10]*** 1 ± 0 [8/8]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 1 ± 0 [8/8] 1 ± 0 [8/8] 0 ± 0 [0/8]
Edema M e e e e e e e 0 ± 0 [0/8] 4 ± 0.19 [8/8] 3.8 ± 0.16 [8/8] 0.4 ± 0.2 [4/7]
F e e e e e e e 0 ± 0 [0/8] 3.8 ± 0.16 [8/8] 3.5 ± 0.33 [8/8] 0.5 ± 0.19 [4/8]
NosedLevel 3
Ethmoid TurbinatedOlfactory Epithelium
Atrophy/loss M 0 ± 0 [0/10] 4 ± 0.17 [9/9]*** 3.6 ± 0.34 [9/9]*** 4 ± 0.24 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.5 ± 0.22 [4/10]* 0 ± 0 [0/8] 4 ± 0 [8/8] 3.1 ± 0.3 [8/8] 0.3 ± 0.16 [2/8]
F 0 ± 0 [0/10] 4.3 ± 0.25 [8/8]*** 4 ± 0.3 [10/10]*** 4 ± 0.24 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.6 ± 0.29 [7/9] 0 ± 0 [0/8] 3.5 ± 0.19 [8/8] 3.5 ± 0.19 [8/8] 0.1 ± 0.13 [1/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 1.4 ± 0.18 [9/9]*** 1.4 ± 0.24 [9/9]*** 1.8 ± 0.28 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.2 ± 0.2 [1/10] 0 ± 0 [0/8] 1.8 ± 0.16 [8/8] 1.5 ± 0.19 [8/8] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 1.1 ± 0.35 [6/8]** 1.6 ± 0.37 [9/10]*** 1.7 ± 0.41 [7/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/9] 0 ± 0 [0/8] 1.6 ± 0.18 [8/8] 1.4 ± 0.18 [8/8] 0 ± 0 [0/8]
Submucosa/Lamina Propria
Loss of nerve
bundles
M 0 ± 0 [0/10] 4.3 ± 0.29 [9/9]*** 3.8 ± 0.32 [9/9]*** 3.9 ± 0.35 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.5 ± 0.22 [4/10]* 0 ± 0 [0/8] 3.1 ± 0.4 [8/8] 2.6 ± 0.32 [8/8] 0.4 ± 0.18 [3/8]
F 0 ± 0 [0/10] 4.3 ± 0.16 [8/8]*** 4.1 ± 0.18 [10/10]*** 3.9 ± 0.31 [9/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.3 ± 0.24 [2/9] 0 ± 0 [0/8] 3.1 ± 0.13 [8/8] 3.6 ± 0.26 [8/8] 0.5 ± 0.19 [4/8]*
Inﬁltrate, mixed
cell
M 0 ± 0 [0/10] 1 ± 0 [9/9]*** 1 ± 0 [9/9]*** 0.9 ± 0.11 [8/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.1 ± 0.1 [1/10] 0 ± 0 [0/8] 1 ± 0 [8/8] 1 ± 0 [8/8] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 0.9 ± 0.13 [7/8]*** 0.9 ± 0.1 [9/10]*** 0.9 ± 0.11 [8/9]*** 0 ± 0 [0/10] 0.1 ± 0.1 [1/10] 0.1 ± 0.11 [1/9] 0 ± 0 [0/8] 1 ± 0 [8/8] 1 ± 0 [8/8] 0 ± 0 [0/8]
Edema M e e e e e e e 0.1 ± 0.13 [1/8] 3.6 ± 0.32 [8/8] 3.4 ± 0.26 [8/8] 0.5 ± 0.19 [4/8]
F e e e e e e e 0 ± 0 [0/8] 3.8 ± 0.16 [8/8] 3 ± 0.33 [8/8] 0.6 ± 0.18 [5/8]
NosedLevel 4
Submucosa/Lamina Propria
Loss of nerve
bundles,
dorsal
meatus/
septum
M 0 ± 0 [0/10] 1.3 ± 0.44 [6/9]** 1.3 ± 0.37 [6/8]** 0.7 ± 0.26 [4/10]* 0 ± 0 [0/10] 0 ± 0 [0/9] 0 ± 0 [0/10] 0 ± 0 [0/8] 3.1 ± 0.34 [8/7] 1.6 ± 0.26 [8/8] 0.1 ± 0.14 [6/7]
F 0 ± 0 [0/10] 1.1 ± 0.48 [4/8]* 1.6 ± 0.27 [9/10]*** 1 ± 0.27 [6/8]** 0 ± 0 [0/10] 0 ± 0 [0/10] 0.1 ± 0.1 [1/10] 0 ± 0 [0/7] 1.8 ± 0.25 [8/8] 1.8 ± 0.45 [7/8]\ 0 ± 0 [0/8]
Inﬁltrate, mixed
cell
M 0 ± 0 [0/10] 0.8 ± 0.28 [5/9]** 0.6 ± 0.18 [5/9]** 0.5 ± 0.34 [8/10] 0 ± 0 [0/10] 0 ± 0 [0/9] 0.1 ± 0.1 [1/10] 0 ± 0 [0/8] 0.9 ± 0.44 [3/8] 0 ± 0 [0/8] 0 ± 0 [0/7]
F 0 ± 0 [ 0/10] 0.8 ± 0.16 [6/8]** 0.6 ± 0.22 [5/10]* 0.5 ± 0.19 [4/8]* 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 0.3 ± 0.16 [2/8] 0.5 ± 0.38 [2/8] 0 ± 0 [0/8]
Edema, dorsal
meatus/
septum
M 0 ± 0 [0/10] 0.6 ± 0.18 [5/9]** 0.3 ± 0.24 [7/9] 0.2 ± 0.2 [9/10] 0 ± 0 [0/10] 0.1 ± 0.1 [1/10] 0.2 ± 0.13 [2/10] 0.1 ± 0.13 [1/8] 0.9 ± 0.46 [4/7] 1.3 ± 0.16 [8/8] 0.2 ± 0.17 [1/6]
F 0 ± 0 [0/10] 0 ± 0 [0/8] 0.3 ± 0.15 [9/10] 0.4 ± 0.18 [5/8]* 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/7] 1.4 ± 0.26 [7/8] 0.9 ± 0.4 [4/8]↥ 0.3 ± 0.16 [2/8]
Larynx
Base of the Epiglottis
Squamous cell
hyperplasia-
metaplasia
M 0.1 ± 0.1 [1/10] 5 ± 0 [1/9]*** 4.8 ± 0.13 [10/10]*** 4.6 ± 0.18 [9/9]*** 1.7 ± 0.26 [9/10]*** 2.5 ± 0.17 [10/10]*** 3 ± 0.21 [10/10]*** 0 ± 0 [0/8] 1.9 ± 0.26 [7/7] 1.3 ± 0.25 [7/8] 0.1 ± 0.13 [1/8]
F 0 ± 0 [0/10] 4.6 ± 0.18 [0/8]*** 4.7 ± 0.15 [10/10]*** 4.4 ± 0.18 [9/9]*** 2.1 ± 0.23 [10/10]*** 2.7 ± 0.21 [10/10]*** 3 ± 0.21 [10/10]*** 0.1 ± 0.13 [1/8] 1 ± 0.31 [5/7] 1.6 ± 0.18 [8/8] 0.5 ± 0.19 [4/8]
Submucosa/Lamina Propria
Inﬁltrate,
mononuclear
cell
M 0.6 ± 0.22 [5/10] 2.2 ± 0.28 [9/9]** 2.2 ± 0.2 [10/10]*** 2.2 ± 0.2 [10/10]*** 1.5 ± 0.22 [9/10]* 1.4 ± 0.27 [9/10]* 1.2 ± 0.2 [9/10] 0.3 ± 0.16 [2/8] 1.1 ± 0.34 [5/7] 1.1 ± 0.3 [6/8] 0.1 ± 0.13 [1/8]
F 0.6 ± 0.24 [4/9] 1.9 ± 0.3 [8/8]** 2.6 ± 0.22 [10/10]*** 2.2 ± 0.22 [9/9]** 0.8 ± 0.2 [7/10] 1.4 ± 0.31 [8/10] 2.1 ± 0.18 [10/10]*** 0.3 ± 0.25 [1/8] 0.9 ± 0.26 [5/7] 1 ± 0.33 [5/8] 0.4 ± 0.18 [4/8]
Ectasia/
congestion,
vascular
M 0.2 ± 0.13 [2/10] 0.9 ± 0.13 [7/8]* 0.8 ± 0.15 [7/9]* 0.9 ± 0.1 [9/10]** 0.4 ± 0.16 [4/10] 0.6 ± 0.16 [6/10] 0.7 ± 0.15 [7/10] 0 ± 0 [0/8] 0.7 ± 0.18 [5/7] 0.8 ± 0.16 [6/8] 0.1 ± 0.13 [1/8]
F 0.1 ± 0.11 [1/9] 0.8 ± 0.16 [6/8]* 0.8 ± 0.13 [8/10]** 0.7 ± 0.17 [6/9]* 0.1 ± 0.1 [1/10] 0.5 ± 0.17 [5/10] 0.5 ± 0.17 [5/10] 0 ± 0 [0/8] 0.1 ± 0.14 [1/7] 0 ± 0 [0/8] 0.1 ± 0.13 [1/8]
Arytenoid Projections
Lower Medial Region
Squamous cell
hyperplasia-
metaplasia
M 0.4 ± 0.16 [4/10] 4.8 ± 0.15 [9/9]*** 4.2 ± 0.2 [10/10]*** 4.5 ± 0.22 [10/10]*** 1 ± 0.15 [9/10]* 1.4 ± 0.16 [10/10]** 2 ± 0.21 [10/10]*** 0 ± 0 [0/8] 2 ± 0.27 [8/8] 1.5 ± 0.46 [6/8] 0.3 ± 0.25 [1/8]
F 0.1 ± 0.1 [1/10] 4.3 ± 0.25 [8/8]*** 4.5 ± 0.17 [10/10]*** 4.2 ± 0.15 [9/9]*** 1.7 ± 0.21 [10/10]*** 1.9 ± 0.18 [10/10]*** 2.2 ± 0.2 [10/10]*** 0.1 ± 0.13 [1/8] 1.9 ± 0.55 [6/8] 2.3 ± 0.47 [7/7] 0 ± 0 [0/8]
Upper Medial Region
Basal cell
hyperplasia
M 0 ± 0 [0/10] 0 ± 0 [0/9] 0.1 ± 0.1 [1/10] 0.1 ± 0.1 [1/10] 0.6 ± 0.16 [6/10]** 1.3 ± 0.15 [10/10]*** 0.9 ± 0.23 [7/10]** 0 ± 0 [0/8] 0.5 ± 0.19 [4/8] 0.3 ± 0.16 [2/8] 0.1 ± 0.13 [1/8]
F 0.1 ± 0.1 [1/10] 0 ± 0 [0/8] 0 ± 0 [0/10] 0 ± 0 [0/9] 1.3 ± 0.37 [6/8]** 1.2 ± 0.28 [7/9]** 1.3 ± 0.33 [7/10]** 0.1 ± 0.13 [1/8] 0.8 ± 0.16 [6/8] 0.8 ± 0.17 [7/6] 0 ± 0 [0/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 4.6 ± 0.18 [9/9]*** 3.9 ± 0.41 [10/10]*** 4.3 ± 0.21 [10/10]*** 0.3 ± 0.21 [2/10] 0.1 ± 0.1 [1/10] 0.7 ± 0.26 [5/10]* 0 ± 0 [0/8] 0.5 ± 0.27 [3/8] 0.5 ± 0.27 [5/8] 0.3 ± 0.25 [1/8]
F 0 ± 0 [0/10] 4.8 ± 0.16 [8/8]*** 4.5 ± 0.17 [10/10]*** 4.2 ± 0.22 [9/9]*** 0.6 ± 0.26 [4/8]* 1.2 ± 0.32 [7/9]*** 1.5 ± 0.37 [8/10]*** 0.1 ± 0.13 [1/8] 1.4 ± 0.53 [5/8] 1 ± 0.37 [4/6] 0 ± 0 [0/8]
Ventral Pouch
Epithelial changes
Basal cell
hyperplasia
M 0.1 ± 0.11 [1/9] 0 ± 0 [0/9] 0.1 ± 0.1 [1/10] 0.3 ± 0.21 [2/10] 0.3 ± 0.15 [3/10] 0.7 ± 0.24 [4/9]* 0.7 ± 0.26 [5/10] 0 ± 0 [0/8] 1.3 ± 0.25 [7/8] 0.6 ± 0.26 [4/8] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 0.1 ± 0.13 [1/8] 0.3 ± 0.21 [2/10] 0.1 ± 0.11 [1/9] 0.3 ± 0.15 [3/10] 1 ± 0.37 [5/10]* 1.2 ± 0.29 [8/10]*** 0 ± 0 [0/8] 0.8 ± 0.25 [5/8] 0.6 ± 0.18 [5/8] 0 ± 0 [0/8]
Squamous cell
metaplasia
M 0 ± 0 [0/10] 4.4 ± 0.44 [9/9]*** 3.6 ± 0.62 [9/10]*** 3.3 ± 0.62 [9/10]*** 0 ± 0 [0/10] 0.2 ± 0.22 [8/9] 0.4 ± 0.27 [2/10] 0 ± 0 [0/8] 0.8 ± 0.37 [3/8] 0.3 ± 0.16 [2/8] 0 ± 0 [0/8]
F 0 ± 0 [0/10] 4.6 ± 0.26 [8/8]*** 3.9 ± 0.55 [9/10]*** 4.4 ± 0.29 [9/9]*** 0 ± 0 [0/10] 0.4 ± 0.31 [8/10] 0.2 ± 0.13 [2/10] 0.1 ± 0.13 [1/8] 0.3 ± 0.16 [2/8] 0.4 ± 0.18 [3/8] 0.1 ± 0.13 [1/8]
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Submucosa/lamina propria
Inﬁltrate,
mononuclear
cell
M 0.3 ± 0.15 [3/10] 1.3 ± 0.25 [7/8]** 1 ± 0.21 [8/10]* 1.2 ± 0.25 [8/10]* 0.5 ± 0.22 [4/10] 0.8 ± 0.33 [5/10] 0.6 ± 0.22 [5/10] 0 ± 0 [0/8] 0.5 ± 0.27 [3/8] 0.8 ± 0.25 [5/8] 0.1 ± 0.13 [1/8]
F 0 ± 0 [0/9] 1.9 ± 0.35 [7/8]*** 1.7 ± 0.3 [9/10]*** 2 ± 0.24 [9/9]*** 0.2 ± 0.13 [2/10] 1.1 ± 0.31 [7/10]** 0.8 ± 0.25 [6/10]** 0.1 ± 0.13 [1/8] 0.3 ± 0.16 [2/8] 0.5 ± 0.38 [2/8] 0 ± 0 [0/8]
Ectasia/
congestion,
vascular
M 0.6 ± 0.16 [6/10] 1 ± 0 [0/8] 1 ± 0 [10/10] 0.9 ± 0.1 [9/10] 0.7 ± 0.15 [3/10] 0.9 ± 0.1 [9/10] 1 ± 0 [10/10] 0.1 ± 0.13 [1/8] 1 ± 0 0.6 ± 0.18 [5/8] 0.3 ± 0.16 [2/8]
[8/8]
F 0.2 ± 0.15 [2/9] 1 ± 0 [0/8]** 0.9 ± 0.1 [9/10]** 1 ± 0 [9/9]** 0.5 ± 0.17 [5/10] 0.6 ± 0.16 [6/10] 0.7 ± 0.15 [7/10] 0.1 ± 0.13 [1/8] 0.5 ± 0.19 [4/8] 0.8 ± 0.16 [6/8] 0.4 ± 0.18 [3/8]
Vocal FoldsdMid-lateral Region
Squamous cell
hyperplasia-
metaplasia
M 0.2 ± 0.13 [2/10] 3.7 ± 0.17 [9/9]*** 3.8 ± 0.29 [10/10]*** 3.8 ± 0.25 [10/10]*** 0.8 ± 0.22 [6/9]* 1 ± 0.17 [8/9]** 1.2 ± 0.33 [7/10]* 0.1 ± 0.13 [1/8] 2.3 ± 0.42 [8/7] 1.5 ± 0.33 [7/8] 0.3 ± 0.25 [1/8]
F 0 ± 0 [0/10] 4.3 ± 0.25 [8/8]*** 4.2 ± 0.13 [10/10]*** 3.8 ± 0.22 [9/9]*** 0.5 ± 0.17 [5/10]* 1.1 ± 0.23 [8/10]*** 1.1 ± 0.23 [8/10]*** 0.4 ± 0.38 [1/8] 1.6 ± 0.46 [6/8]* 1.4 ± 0.32 [7/8]* 0.1 ± 0.13 [1/8]
Tracheal BifurcationdCarina
Basal cell
hyperplasia
M 0.7 ± 0.24 [5/9] 2.9 ± 0.55 [7/7]** 2.6 ± 0.26 [8/8]*** 2 ± 0.33 [9/10]** 0.5 ± 0.22 [4/10] 0.6 ± 0.31 [4/10] 1 ± 0.3 [7/10] 0.6 ± 0.37 [2/7] 1.1 ± 0.26 [6/7] 0.2 ± 0.17 [1/6] 0.6 ± 0.26 [4/8]
F 0.1 ± 0.11 [1/9] 2 ± 0.46 [7/8]** 2.1 ± 0.31 [9/10]*** 2.6 ± 0.46 [8/8]*** 0.4 ± 0.16 [4/10] 0.6 ± 0.24 [4/9] 1.1 ± 0.31 [7/9]** 0 ± 0 [0/7] 0.4 ± 0.2 [3/7] 1 ± 0.33 [5/8] 0.7 ± 0.29 [4/7]
Squamous cell
metaplasia
M 0 ± 0 [0/9] 1.4 ± 0.65 [4/8]* 0.3 ± 0.21 [2/10] 1.1 ± 0.43 [5/10]* 0.1 ± 0.1 [1/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 0 ± 0 [0/7] 0 ± 0 0 ± 0 [0/8]
[8/8]
F 0 ± 0 [0/10] 0.8 ± 0.41 [3/8]* 0.2 ± 0.13 [2/10] 0.3 ± 0.16 [6/8] 0 ± 0 [0/10] 0 ± 0 [0/9] 0 ± 0 [0/10] 0 ± 0 [0/7] 0 ± 0 [0/7] 0 ± 0 [8/8] 0 ± 0 [0/7]
Tracheal Wall
Goblet cell
hyperplasia/
hypertrophy
M 0.8 ± 0.16 [2/8] 3.1 ± 0.45 [9/9]** 2.5 ± 0.45 [9/10]** 3.5 ± 0.45 [10/10]*** 0.6 ± 0.22 [5/10] 0.9 ± 0.2 [7/9] 0.7 ± 0.21 [6/10] 0.1 ± 0.13 [1/8] 0.6 ± 0.2 [4/7] 1.3 ± 0.25 [7/8] 0.1 ± 0.13 [1/8]
F 0.9 ± 0.23 [2/8] 1.3 ± 0.31 [6/8] 1.8 ± 0.29 [10/10]* 2.4 ± 0.41 [0/9]* 0.4 ± 0.16 [4/10] 0.4 ± 0.18 [5/8] 0.2 ± 0.15 [2/9]↥ 0.4 ± 0.3 [2/7] 0.7 ± 0.29 [4/7] 0.6 ± 0.18 [5/8] 0.1 ± 0.14 [1/7]
Left LungdIntra-alveolar Changes
Unpigmented
macrophages
M 0.1 ± 0.1 [1/10] 1 ± 0 [9/9]*** 1 ± 0 [10/10]*** 1 ± 0 [10/10]*** 0.3 ± 0.15 [3/10] 0.2 ± 0.13 [2/10] 0.1 ± 0.1 [1/10] 0.8 ± 0.16 [6/8] 1 ± 0 [8/8] 1 ± 0 0.5 ± 0.19 [4/8]
[8/8]
F 0.1 ± 0.1 [1/10] 1 ± 0 [8/8]*** 1 ± 0 [10/10]*** 1 ± 0 [9/9]*** 0.2 ± 0.13 [2/10] 0 ± 0 [0/10] 0.4 ± 0.16 [4/10] 0.6 ± 0.18 [5/8] 1 ± 0 [8/8] 1 ± 0 [7/7] 0.6 ± 0.18 [3/8]
Pigmented
macrophages
M 0.1 ± 0.1 [1/10] 1 ± 0 [9/9]*** 1 ± 0 [10/10]*** 1 ± 0 [10/10]*** 0 ± 0 [0/10] 0.4 ± 0.16 [6/10] 0.2 ± 0.13 [2/10] 0 ± 0 [0/8] 1 ± 0 1 ± 0 0 ± 0 [0/8]
[8/8] [8/8]
F 0 ± 0 [0/10] 1 ± 0 [8/8]*** 1 ± 0 [10/10]*** 1 ± 0 [9/9]*** 0 ± 0 [0/10] 0.1 ± 0.1 [9/10] 0.1 ± 0.1 [1/10] 0 ± 0 [0/8] 1 ± 0 1 ± 0 0 ± 0 [0/8]
[8/8] [7/7]
Macrophage
aggregates
M 0 ± 0 [0/10] 3.6 ± 0.58 [9/9]*** 3.9 ± 0.35 [10/10]*** 3.1 ± 0.53 [10/10]*** 0.1 ± 0.1 [1/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 5 ± 0 4.5 ± 0.19 [8/8] 0.1 ± 0.13 [1/8]
[8/8]
F 0 ± 0 [0/10] 3 ± 0.46 [8/8]*** 3.3 ± 0.54 [9/10]*** 3.6 ± 0.47 [8/9]*** 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/10] 0 ± 0 [0/8] 4.3 ± 0.25 [8/8] 3.6 ± 0.69 [7/7] 0 ± 0 [0/8]
Results are presented as mean ± standard error. The sample size is in parentheses. Difference from sham group at 90d: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001.
Abbreviations: M, male; F, female; LM, low menthol; HM, high menthol; R, recovery groups.
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A. Oviedo et al. / Regulatory Toxicology and Pharmacology 81 (2016) S93eS122S112presence of menthol in MS did not introduce any novel effects, nor
did it alter the severity and/or incidence of histopathological
ﬁndings observed from 3R4F MS exposure alone.
3.8.3. Trachea
Alterations in the trachea which were statistically signiﬁcantly
higher in the MRC groups compared with sham and THS2.2M
included basal cell hyperplasia, squamous cell metaplasia, and
goblet cell hyperplasia. There were no differences in severity and
incidence of the ﬁndings between the MRC groups and the 3R4F
group, indicating that the presence of menthol in MS had no effect
on the alterations in the trachea.
In THS2.2M-exposed groups, all observed ﬁndings were
considered incidental.
There was complete reversal of adaptive changes and near-
complete reversal of inﬂammatory inﬁltrates following recovery
from MRC MS exposure.
3.8.4. Lung
In the left lung, MS-induced histologic ﬁndings included basal
cell hyperplasia, goblet cell hyperplasia, squamous metaplasia of
the main-stem bronchus, basal cell hyperplasia of the lower bron-
chiolar epithelium, unpigmented and pigmented macrophages
scattered within alveoli, dense macrophage aggregates in alveolar
spaces, and alveolar type 2 pneumocyte hyperplasia. In the
THS2.2MMA-exposed groups, all observed ﬁndings were of similar
incidence and/or severity compared with sham, and slightly devi-
ating ﬁndings were considered incidental.
Overall, ﬁndings in the lung following 3R4F and MRC MS
exposure were similar. Basal cell hyperplasia and goblet cell hy-
perplasia along the bronchus, along with squamous cell metaplasia
and basal cell hyperplasia of the lower bronchioles, were statisti-
cally signiﬁcantly higher compared with sham. Following the 42-
day post-inhalation recovery period, there was complete reversal
of basal cell and goblet cell hyperplasia.
In the lower airways and within the alveoli, pigmented and
unpigmented macrophages were observed at 100% incidence in
MRC MS-exposed groups. The severity of macrophage aggregates
within the alveoli was comparable between the MRC groups. These
ﬁndings were all statistically signiﬁcantly higher than in the sham
and THS2.2M exposure groups. Aggregates of pigment-laden
alveolar macrophages were scattered randomly throughout the
lower airways adjacent to the alveolar ducts, and were often
associated with slight local hyperplasia of alveolar epithelial cells.
Incidence of type 2 pneumocyte hyperplasia was associated with
the severity of macrophage aggregates. Following a 42-day recov-
ery period, there was a notable increase in macrophage aggregates
within alveoli in MRC MS-exposed groups. This was accompanied
by an increased incidence of type 2 pneumocyte hyperplasia.
No differences were observable in any of the histopathological
endpoints in MRC groups compared with the 3R4F group.
Furthermore, the presence of menthol in MS did not introduce any
novel effects, nor did it alter the severity and/or incidence of his-
topathological ﬁndings observed from 3R4F MS exposure alone.
3.9. Transcriptome and proteome responses (“OECD plus”)
As part of our overall systems toxicology assessment framework
(Sturla et al., 2014), the standard toxicological endpoints were
complemented by measurements of global transcriptome and
proteome changes in RNE and lung tissue from animals that were
exposed alongside those from the main study. Effects on the tran-
scriptomeweremeasured bymicroarray expression proﬁling, and a
robust isobaric tag-based mass spectrometry method was
employed to quantify changes in the proteome (Phillips et al.,2015b; Titz et al., 2014). Here, we report on the global systems
response patterns that summarize the molecular perturbations for
the different exposure conditions. More details and mechanistic
insights are provided in our accompanying manuscript (Kogel et al.,
2016 (in this issue)).
3.9.1. Systems response proﬁles of RNE
To assess the response of the RNE transcriptome, differentially
expressed genes (DEGs) were ﬁrst identiﬁed for each exposure
group in comparisonwith their respective sham groups as all genes
with FDR-adjusted p-values below 0.05. Fig. 3A and B summarize
the exposure response of these differentially expressed genes for all
smoke and aerosol exposure groups. Note that the overall response
proﬁles are discussed here, and a more detailed biological analysis
of the molecular exposure response is presented in the accompa-
nying manuscript (Kogel et al., 2016 (in this issue)). For both male
and female rats, THS2.2M MA exposure induced fewer changes in
the RNE transcriptome compared with MRC MS exposures. For
male rats, the highest number of DEGs was observed in the
MRC(HM) group (7729 DEGs). For female rats, the highest number
of DEGs was observed in the MRC(LM) group (8054 DEGs). In
contrast, only 1 DEG was found in male rats and no DEGs in female
rats after exposure to THS2.2M Medium MA at the same nicotine
concentration (23 mg nicotine/l). Exposure to higher nicotine con-
centrations led to 9 DEGs in the respiratory epithelium in male rats
and 2118 DEGs in female rats of the THS2.2M High groups. After the
recovery period, only 5% of all DEGs were still statistically signiﬁ-
cantly differentially expressed in the THS2.2M High group relative
to sham.
Quantitative proteomics revealed up to 1300 signiﬁcantly
differentially expressed proteins (DEPs) in the RNE of MRC MS-
exposed rats in comparison with sham (FDR adjusted p-value
<0.05) (Fig. 4A) e with a higher number of DEPs in female than in
male rats. In contrast, THS2.2M MA-exposed rats showed much
lower differential protein expression in the RNE (Fig. 4A). In the
THS2.2M Low and THS2.2MMedium groups, a maximum of 7 DEPs
was found; the differential expression response to THS2.2 High was
more pronounced, with 266 (males) and 478 (females) DEPs. The
25 proteins with the overall highest fold-change included several
epithelial cell markers (Krt6a, Krt13, Sprr1a, Clu, Sfn), and were
indicative of gross changes in the cellular architecture of the
epithelium upon MS exposure (see Discussion section and Kogel
et al. (Kogel et al., 2016 (in this issue))). These proteins exempliﬁed
the overall trends, and were regulated in the same direction upon
THS2.2M MA exposure (up- or downregulated) as after MRC MS
exposure (Fig. 4C). However, consistently, the fold-changes were
much lower upon MA exposure, and statistical signiﬁcance was
generally only reached after exposure to the highest concentration
of THS2.2MMA.Whereas female rats exposed toMRC(HM) showed
only a partial recovery after 42 days post-exposure, all differentially
expressed proteins did recover for the THS2.2M High exposure
condition (Fig. 4C).
Taken together, both the transcriptome and proteome response
proﬁles of RNE supported an overall reduction of the THS2.2M
aerosol-induced molecular effects compared with reference smoke
exposure. In addition, the molecular changes induced by THS2.2M
aerosol appeared largely to revert after the 42-day recovery period.
3.9.2. Systems response proﬁles of lung tissue
The molecular response of rat lung tissue to the tested exposure
conditions was analyzed by both transcriptomics and proteomics.
Here, the overall response proﬁles are discussed; a more detailed
analysis of the affected transcripts and proteins is presented in the
accompanying manuscript (Kogel et al., 2016 (in this issue)). Of
note, the number of DEGs identiﬁed in the lung tissue of rats
Table 7b
Statistically signiﬁcant differences in histopathological ﬁndings in the respiratory tract at the end of the 90-day and post-inhalation periods.
Parameter THS2.2M Medium vs.
MRC(LM)
THS2.2M High vs.
MRC(HM).
MRC (HM) vs. 3R4F Sham R vs.
Sham
3R4F R vs.
3R4F
MRC(HM) R vs.
MRC(HM)
THS2.2M High R vs.
THS2.2M High
NosedLevel 1
Nasal SeptumdRespiratory Epithelium
Basal cell hyperplasia M Y* ¼ ¼ ¼ Y*** Y** Y*
F Y*** ¼ ¼ ¼ Y* Y*** ¼
Goblet cell hyperplasia/hypertrophy M ¼ ¼ ¼ ¼ [** [** [**
F ¼ Y* ¼ ¼ [*** [*** [**
Goblet cell loss M Y*** ¼ ¼ ¼ Y** Y** Y***
F Y*** ¼ ¼ ¼ Y*** Y*** Y***
Squamous cell metaplasia M Y*** Y* ¼ ¼ Y** ¼ Y**
F Y*** Y** ¼ ¼ Y*** Y* Y**
Lateral WalldRespiratory Epithelium
Basal cell hyperplasia M ¼ ¼ ¼ ¼ ¼ Y* ¼
F ¼ ¼ ¼ ¼ ¼ ¼ Y*
Squamous cell metaplasia M Y*** Y* ¼ ¼ Y* ¼ ¼
F Y*** ¼ ¼ ¼ ¼ ¼ ¼
Maxilloturbinate - Respiratory Epithelium
Basal cell hyperplasia M ¼ ¼ ¼ ¼ [** ¼ ¼
F [* ¼ ¼ ¼ [* ¼ ¼
Squamous cell metaplasia M Y*** Y** ¼ ¼ Y*** ¼ Y***
F Y*** ¼ ¼ ¼ Y*** Y** Y**
NasoturbinatedRespiratory Epithelium
Basal cell hyperplasia M ¼ ¼ ¼ ¼ ¼ ¼ ¼
F [* ¼ ¼ [* ¼ ¼ ¼
Squamous cell metaplasia M Y*** Y* ¼ ¼ Y* ¼ ¼
F Y*** Y** ¼ ¼ ¼ Y*** Y*
Dorsal MeatusdRespiratory Epithelium
Squamous cell metaplasia M Y*** Y* Y* ¼ Y*** ¼ Y**
F Y*** ¼ ¼ ¼ Y*** Y* Y**
Submucosa/Lamina Propria
Inﬁltrate, mixed cells (incidence) M Y*** ¼ ¼ ¼ ¼ ¼ ¼
F Y*** ¼ ¼ ¼ ¼ ¼ ¼
Nasal CavitydLumen
Necrotic cellular debris M Y*** ¼ ¼ ¼ ¼ ¼ ¼
F ¼ ¼ ¼ ¼ ¼ ¼ ¼
Amorphous eosinophilic material M Y*** ¼ ¼ ¼ ¼ ¼ ¼
F Y** Y* ¼ ¼ Y* Y**
NosedLevel 2
Dorsal MeatusdOlfactory Epithelium
Atrophy/loss M Y*** Y*** ¼ ¼ ¼ Y** ¼
F Y*** Y*** ¼ ¼ ¼ ¼ ¼
Squamous cell metaplasia M Y*** Y*** ¼ ¼ Y* Y* ¼
F Y*** Y*** ¼ ¼ Y* ¼ ¼
NasoturbinatedRespiratory Epithelium
Basal cell hyperplasia M Y*** Y*** ¼ ¼ Y*** Y*** ¼
F Y*** Y* ¼ ¼ Y** Y** Y**
Squamous cell metaplasia M Y*** Y** ¼ ¼ Y* ¼
F Y** Y** ¼ ¼ Y** ¼ Y**
Submucosa/Lamina Propria
Loss of nerve bundlesddorsal meatus M Y*** Y*** ¼ ¼ Y* Y** ¼
F Y*** Y*** ¼ ¼ Y** ¼ Y*
Inﬁltrate, mixed cell M Y*** Y*** ¼ ¼ ¼ ¼ ¼
F Y*** Y*** ¼ ¼ ¼ ¼ ¼
Edema M ¼ ¼ ¼ ¼ ¼ ¼ ¼
F ¼ ¼ ¼ ¼ ¼ ¼ ¼
(continued on next page)
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Table 7b (continued )
Parameter THS2.2M Medium vs.
MRC(LM)
THS2.2M High vs.
MRC(HM).
MRC (HM) vs. 3R4F Sham R vs.
Sham
3R4F R vs.
3R4F
MRC(HM) R vs.
MRC(HM)
THS2.2M High R vs.
THS2.2M High
NosedLevel 3
Ethmoid TurbinatedOlfactory Epithelium
Atrophy/loss M Y*** Y*** ¼ ¼ ¼ Y* ¼
F Y*** Y*** ¼ ¼ Y* ¼ ¼
Squamous cell metaplasia M Y*** Y*** ¼ ¼ ¼ ¼ ¼
F Y*** Y*** ¼ ¼ ¼ ¼ ¼
Submucosa/Lamina Propria
Loss of nerve bundles M Y*** Y*** ¼ ¼ Y* Y* ¼
F Y*** Y*** ¼ ¼ Y*** ¼ ¼
Inﬁltrate, mixed cell M Y*** Y** ¼ ¼ ¼ ¼ ¼
F Y** Y** ¼ ¼ ¼ ¼ ¼
Edema M ¼ Y*** ¼ ¼ ¼ ¼ ¼
F ¼ Y*** ¼ ¼ ¼ ¼ ¼
NosedLevel 4
Submucosa/Lamina Propria
Loss of nerve bundles, dorsal meatus/septum M Y** Y* ¼ ¼ [* ¼ [*
F Y*** Y** ¼ ¼ ¼ ¼ ¼
Inﬁltrate, mixed cell M Y* ¼ ¼ ¼ ¼ ¼
F Y* Y* ¼ ¼ ¼ ¼ ¼
Edema, dorsal meatus/septum M ¼ ¼ ¼ ¼ ¼ ¼ [**
F ¼ Y* ¼ ¼ [** ¼ ¼
Larynx
Base of the Epiglottis
Squamous cell hyperplasia-metaplasia M Y*** Y*** ¼ ¼ Y*** Y*** Y***
F Y*** Y*** ¼ ¼ Y*** Y*** Y***
Submucosa/Lamina Propria
Inﬁltrate, mononuclear cell M Y* Y** ¼ ¼ Y* Y** Y*
F Y** ¼ ¼ ¼ Y* Y*** Y*
Ectasia/congestion, vascular M ¼ ¼ ¼ ¼ ¼ Y* ¼
F ¼ ¼ ¼ ¼ Y* ¼ Y**
Arytenoid Projections
Lower Medial Region
Squamous cell hyperplasia-metaplasia M Y*** Y*** ¼ Y* Y*** Y*** Y***
F Y*** Y*** ¼ ¼ Y** Y*** Y**
Upper Medial Region
Basal cell hyperplasia M [*** [** ¼ ¼ [* Y* ¼
F [*** [** ¼ ¼ [** Y** [**
Squamous cell metaplasia M Y*** Y*** ¼ ¼ Y*** ¼ Y***
F Y*** Y*** ¼ ¼ Y*** Y** Y**
Ventral Pouch
Epithelial Changes
Basal cell hyperplasia M [* ¼ ¼ ¼ [*** Y* ¼
F ¼ [** ¼ ¼ [* Y** [*
Squamous cell metaplasia M Y*** Y** ¼ ¼ Y*** ¼ Y**
F Y*** Y*** ¼ ¼ Y*** ¼ Y***
Submucosa/Lamina Propria
Inﬁltrate, mononuclear cell M ¼ ¼ ¼ ¼ ¼ ¼ ¼
F ¼ Y** ¼ ¼ Y** Y* Y**
Ectasia/congestion, vascular M ¼ ¼ ¼ ¼ ¼ Y** ¼
F ¼ ¼ ¼ ¼ ¼ ¼ ¼
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Vocal FoldsdMid-lateral Region
Squamous cell hyperplasia-metaplasia M Y*** Y*** ¼ ¼ Y* Y* Y***
F Y*** Y*** ¼ ¼ Y** Y** Y***
Tracheal BifurcationdCarina
Basal cell hyperplasia M Y** Y* ¼ ¼ Y* ¼ Y**
F Y** Y* ¼ ¼ Y* ¼ Y*
Squamous cell metaplasia M ¼ Y* ¼ ¼ Y* ¼ Y*
F ¼ ¼ ¼ ¼ ¼ ¼ ¼
Tracheal Wall
Goblet cell hyperplasia/hypertrophy M Y** Y*** ¼ Y* Y** Y* Y**
F Y** Y*** ¼ ¼ ¼ ¼ Y**
Left LungdIntra-alveolar Changes
Unpigmented macrophages M Y*** Y*** ¼ [* ¼ ¼ ¼
F Y*** Y* ¼ [* ¼ ¼ ¼
Pigmented macrophages M Y* Y*** ¼ ¼ ¼ ¼ ¼
F Y*** Y*** ¼ ¼ ¼ ¼ ¼
Macrophage aggregates M Y*** Y*** ¼ ¼ [* ¼ ¼
F Y*** Y*** ¼ ¼ [* ¼ ¼
Difference between groups: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Symbols, Y indicates lower response in group 1 than in 2;[ indicates higher response in group 1 than in 2;¼ indicates no signiﬁcance. Abbreviations:
M, male; F, female; LM, low menthol; HM, high menthol; R, recovery groups.
Table 8a
Laryngeal epithelial thickness at the end of the 90-day and post-inhalation periods.
Localization OECD 90 þ 42d
Sham 3R4F MRC(LM) MRC(HM) THS2.2M Low THS2.2M Medium THS2.2M High Sham R 3R4F R MRC(HM) R THS2.2M High R
Base of epiglottis [mm] M 22 ± 1.2 [10] 61.7 ± 2.1 [9]*** 70 ± 3.2 [10]*** 63 ± 3.5 [10]*** 39.3 ± 2.4 [10]*** 48 ± 2.4 [10]*** 51.2 ± 2.9 [10]*** 21.9 ± 1 [7] 34.9 ± 3.2 [8] 32.3 ± 2.2 [7] 23.9 ± 1.4 [8]
F 18.8 ± 0.9 [10] 69.6 ± 4.2 [8]*** 67.8 ± 3.5 [10]*** 64.2 ± 4 [9]*** 37.7 ± 2.2 [10]*** 40.6 ± 1.6 [10]*** 50.5 ± 3.3 [10]*** 21.5 ± 1.6 [8] 29.8 ± 1.7 [8] 29.2 ± 1.9 [8] 22.8 ± 1.1 [8]
Lateral ﬂoor [mm] M 13 ± 0.8 [9] 37.7 ± 1.9 [8]*** 37.2 ± 1.6 [10]*** 36.8 ± 2.3 [10]*** 16.1 ± 0.8 [10]*** 21.4 ± 1.3 [10]*** 27.4 ± 2.6 [8]*** 12 ± 0.8 [8] 25.1 ± 2.2 [8] 25.4 ± 1.3 [7] 11.7 ± 0.3 [8]
F 10.5 ± 0.4 [10] 41.3 ± 3.4 [6]*** 38.8 ± 2.7 [9]*** 37.4 ± 1.7 [9]*** 16.3 ± 0.7 [10]*** 18.4 ± 1 [9]*** 25.4 ± 1.8 [8]*** 10.8 ± 1.3 [8] 22.1 ± 1.8 [8] 22.6 ± 1.1 [6] 11.6 ± 0.5 [8]
Arytenoid projections [mm] M 19.8 ± 0.6 [10] 49 ± 3.1 [9]*** 45.3 ± 2.8 [10]*** 46 ± 1.5 [10]*** 24.1 ± 0.8 [10]*** 30.1 ± 1.2 [10]*** 31 ± 1.3 [10]*** 17.2 ± 0.5 [8] 31.9 ± 1.2 [8] 27.9 ± 1.6 [8] 18.2 ± 0.6 [8]
F 18.2 ± 0.5 [10] 48.6 ± 2.6 [8]*** 48.8 ± 1.3 [10]*** 45.9 ± 1.7 [9]*** 24.1 ± 0.8 [9]*** 27.1 ± 0.6 [10]*** 30.1 ± 1.2 [10]*** 17.3 ± 1 [8] 27.9 ± 2 [8] 27.5 ± 1.1 [8] 18 ± 1 [8]
Results are presented as mean ± standard error. The sample size is in parentheses. Difference from sham group at 90d: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Abbreviations: M, male; F, female; LM, lowmenthol; HM,
high menthol; R, recovery groups.
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Table 8b
Statistically signiﬁcant differences in larynx epithelial thickness at the end of the 90-day and post-inhalation periods.
Localization 90d 90 þ 42d
THS2.2M
Medium vs. MRC(LM)
THS2.2M High vs.
MRC(HM).
MRC (HM) vs.
3R4F
Sham R vs.
Sham
3R4F R vs.
3R4F
MRC(HM) R vs.
MRC(HM)
THS2.2M High R vs. THS2.2M High
Base of epiglottis M Y*** Y* ¼ ¼ Y*** Y*** Y***
F Y*** Y** ¼ ¼ Y*** Y*** Y***
Lateral ﬂoor M Y*** Y*** ¼ ¼ Y*** Y*** Y***
F Y*** Y*** ¼ ¼ Y*** Y*** Y***
Arytenoid projections M Y*** Y*** ¼ ¼ Y*** Y*** Y***
F Y*** Y*** ¼ ¼ Y*** Y*** Y***
Difference between groups: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001. Symbols, Y indicates lower response in group 1 than in 2; [ indicates higher response in group 1
than in 2; ¼ indicates no signiﬁcance. Abbreviations: M, male; F, female; LM, low menthol; HM, high menthol; R, recovery groups.
A. Oviedo et al. / Regulatory Toxicology and Pharmacology 81 (2016) S93eS122S116exposed to the reference cigarette controls was approximately one
third of the number of DEGs found in the RNE. THS2.2M exposure
resulted in fewer DEGs than reference cigarette exposure e even at
the high exposure concentration of 50 mg/l nicotine for THS2.2M vs.
23 mg/l nicotine for the MRC. For example, in female rats, THS2.2M
High induced 45 DEGs, whereas 1245, 2865, and 1972 DEGs were
induced by 3R4F, MRC(LM), and MRC(HM), respectively. In addi-
tion, the gene expression fold-changes compared with sham-
exposed rats were less pronounced in THS2.2M-exposed lung tis-
sue than in reference cigarette-exposed lung tissue (Fig. 5). Forty-
two days after THS2.2M High MA exposure, all genes except one
reverted to sham-level expression.
The lung proteome was also clearly affected by exposure to
MRCs (Fig. 6). The expression levels of only a few proteins in theFig. 3. Effects of MS and THS2.2M exposure on the nasal epithelium transcriptome. Heatma
which at least one comparison induced a signiﬁcant change. The color scaling is done based olung of female rats were statistically signiﬁcantly changed in the
THS2.2M High group, i.e. a maximum of 16 DEPs for THS2.2M High
exposure vs. 168 DEPs for MRC(HM) exposure (numbers for iTRAQ®
set 2, see Materials and Methods section). This global response
pattern was further exempliﬁed by the 25 proteins with the
greatest overall response, which included upregulated immune
response proteins (e.g. Lcn2), oxidative stress and xenobiotic
response proteins (e.g. Nqo1, Sod2, Aldh3a1, and Akr1b8), and lipid
metabolism proteins (e.g. Lipa and Fabp5) (see Discussion section
and Kogel et al. (Kogel et al., 2016 (in this issue))). These proteins
demonstrated much lower fold-changes for THS2.2M exposure
than after exposure to the reference cigarettes (Fig. 6B). In addition,
all proteins with changed expressions after THS2.2MHigh exposure
recovered after 42 days post-exposure (Fig. 6C).p representing the log2(fold-change)/max(abs(log2(fold-change))) for all the genes for
n the absolute values. A) male rats, B) female rats; LM, lowmenthol, HM, high menthol.
Fig. 4. Effects of MS and THS2.2M exposure on the nasal epithelium proteome. (A) Differential protein expression proﬁles after 90 days of exposure. Each vertical bar chart shows
the protein fold-changes (length of bar) and their signiﬁcance (black FDR-adjusted p < 0.05, grey FDR-adjusted p > 0.05, not signiﬁcant) for one exposure group compared with
sham exposed animals. Only proteins signiﬁcantly differentially expressed in at least one group are shown. The proteins are ranked from top to bottom by the sum of their fold-
changes, i.e. strongly and consistently upregulated proteins are at the top. (B) Differential expression heatmap for the top 25 (by absolute fold-change) differentially expressed
proteins after 90 days of exposure. Each column represents an exposure group, each row a differentially expressed protein (FDR-adjusted p-value <0.05 for any group). The color of
the matrix indicates the fold-change compared with sham exposed animals (see color key); “*” indicates signiﬁcant differential expression (FDR-adjusted p-value <0.05). (C)
Evaluation of recovery effects. The volcano plots show the signiﬁcance (y-axis, log10 FDR-adjusted p-value) and the effect size (x-axis, log2 fold-change) compared with the
respective sham groups. Signiﬁcantly up- and downregulated proteins are indicated with red and blue dots, respectively. Note that two different isobaric-tag sets were deﬁned for the
90-day exposure effect and the 90 þ 42d recovery effect (see methods). With this, data for the same exposure group in panels A and B and panel C are not necessarily identical. LM, low
menthol, HM, high menthol.
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The main objective of the current study was to characterize
toxicological effects of MA from THS2.2M, including pulmonary
inﬂammation, and to compare themwith those elicited byMS from
MRC in a 90-day sub-chronic rat inhalation study. The current
report provides a comprehensive assessment of all endpoints
required by the OECD Test Guideline 413, with the additional
strength of providing supplementary endpoints from molecular
BALF analysis, gene expression and proteomic analysis from nasal
epithelium and lung tissue, shedding light on the molecular basis
for the observed changes.
Further molecular endpoints, are described in full detail in Kogel
et al.(Kogel et al., 2016 (in this issue)). The used study design is
however not suited for assessing behavioral aspects of the use of
mentholated cigarettes.
Test atmospheres were generated and diluted to target nicotine
concentrations in MA and MS according to ISO 3308 (3308:2012,
2012). In contrast to other cigarette smoke inhalation studies
where TPM was used as a dosing parameter (Fujimoto et al., 2015;
Terpstra et al., 2003), nicotine concentration in the test atmosphere
was used in this study for two reasons. First, TPM from cigarettes
and aerosols from heat-not-burn tobacco products have completely
different compositions. TPM from 3R4F consists of approximately
32% water, whereas TPM from THS2.2M consists of 68% water;
nicotine levels in THS2.2M are 30% lower than those in 3R4F ciga-
rettes (Roemer et al., 2004). As nicotine is present in the aerosols of
both cigarettes and THS2.2M, it is used as the dosing parameter
here. Second, exposure based on nicotine levels better reﬂects
human smoking behavior. It has been shown that smokers adapt
their smoking behavior, and to a lesser extent cigaretteconsumption, to achieve a certain nicotine uptake when smoking
cigarettes that contain less nicotine (Scherer and Lee, 2014).
Exposure concentrations were chosen according to OECD rec-
ommendations, i.e. that the exposure should be conducted at
concentrations low enough to avoid causing marked pain and
distress, yet sufﬁcient to extend the concentration-response curve
to levels that reach the regulatory and scientiﬁc objective of the
test. The concentrations selected were based on the results of a
concentration range-ﬁnding study, according to OECD guideline
413 (data not shown). For MRCs and 3R4F, the maximum exposure
concentration was limited to a 23 mg nicotine/l test atmosphere
because of the high CO level which leads to COHb proportions of up
to 26.5%. In contrast, the maximum THS2.2M exposure concentra-
tionwas driven by tolerance to nicotine, because of the lower levels
of CO and other constituent chemicals in the diluted aerosol. Based
on the results of a range-ﬁnding study, the maximum nicotine
concentration in the test atmosphere for THS2.2Mwas set at 50 mg/
l. For a rat of 300 g, with a theoretical respiratory minute volume of
200 ml and a daily exposure of 6 h, the calculated daily nicotine
dose is (50 mg/l  0.2 l/min  360 min)/0.3 kg ¼ 12 mg/kg. This
corresponds to a daily nicotine uptake of 720 mg for a human being
of 60 kg, or the nicotine content of approximately 700 cigarettes
per day, if 100% retention is considered. Using a more conservative
approach based on body surface area as described in an FDA
guidance for industry document (FDA, 2005), the Human Equiva-
lent Doses (HED) for a rat exposed to 12 mg/kg corresponds to a
human daily exposure of 12 mg/kg/6.2 or 1.94 mg/kg nicotine. For a
human being of 60 kg, this corresponds to the uptake of 116 mg
nicotine, or slightly more than 100 cigarettes per day. Nicotine
serum analysis showed that exposure to 50 mg/l nicotine for 6 h led
to nicotine concentrations in blood of 762 ng/ml in male and
Fig. 5. Effects of MS and THS2.2M exposure on the lung transcriptome. Heatmap representing the log2(fold-change)/max(abs(log2(fold-change))) for all the genes for which at least
one comparison induced a signiﬁcant change. The color scaling is done based on the absolute values. A) male rats, B) female rats.
Fig. 6. Effects of MS and THS2.2M exposure on the lung proteome. As in Fig. 4, but showing the exposure effects on the lung proteome.
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higher, respectively, than nicotine levels found in humans
(Benowitz et al., 1988; Hukkanen et al., 2005; Rose et al., 1999).Target nicotine concentrations were conﬁrmed in MA from
THS2.2 and MS from MRCs and 3R4F, and particle size distribution
measurements indicated that particles were equally respirable in
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In line with the analytical chemistry results, toxicologically-
relevant smoke constituents were dramatically reduced in the
THS2.2M MA compared with 3R4F (Schaller et al., 2016a (in this
issue)). The concentrations of aldehydes measured in the diluted
MA from THS2.2M were approximately only 10%e25% of the con-
centrations present in MS from MRCs; the concentrations of CO
were reduced by up to 98%.
Exposure efﬁciency was conﬁrmed by monitoring the levels of
nicotine, cotinine, menthol, and M-I in blood plasma. A dose-
dependent increase was observed, in correspondence with test
atmosphere in THS2.2M MA- and MRC MS-exposed groups.
Female rats had approximately 50% higher nicotine levels in
blood compared with male rats, while cotinine levels in blood and
nicotine metabolites in urine were similar in the two sexes. This
may indicate differences inmetabolic rates in female rats compared
with male rats, as suggested by Harrod et al. (2007). It is note-
worthy that the quantities of recovered nicotine metabolites in the
urine of the THS2.2M Medium group were higher than the quan-
tities of nicotine metabolites in rats exposed to MS at the same test
atmosphere nicotine exposure concentration, i.e.23 mg/l. This is
most probably due to the fact that MS is a more potent respiratory
irritant than MA from THS2.2M due to the test atmosphere con-
centrations of carbonyls, and supported by the data reported here.
The respiratory frequency, which is the main driver of the respi-
ratory minute volume (but not measured in the current study), was
lower in the MS-exposed groups than in sham and THS2.2M
Medium-exposed groups. Therefore, it can be anticipated that the
uptake of aerosol would be higher in the THS2.2M-exposed groups
than in theMS groups. This is consistent with ﬁnding from previous
studies (such as Terpstra et al., 2003), and has been described for a
similar product (Wong et al., 2016 (in this issue)).
CO concentrations in the test atmospheres were consistent with
the nicotine exposure levels when cigarettes were used, and there
was a good correlation between the proportions of COHb and CO
concentrations in the test atmospheres. The concentrations of CO in
the test atmospheres of THS2.2M, however, were so low that COHb
levels were only marginally higher than those observed in sham-
exposed rats.
In line with reduced quantities of aldehydes and CO in MA from
THS2.2M, the concentrations of representative urinary metabolites
of toxicologically-relevant smoke constituents (acrolein, NNK,
benzene, acrylonitrile) were much lower than those in MRC MS-
exposed groups, conﬁrming that rats inhaling MA from THS2.2M
were exposed to lower quantities of these constituents.
The decrease in BWgain of male THS2.2MMA-exposed rats was
statistically signiﬁcantly less pronounced than in rats exposed to
MRC after 90 days of exposure. This can be attributed to the low
levels of toxicologically-relevant smoke constituents such as acro-
lein in the MAwhich contribute to the decreased BWgain observed
in smoke-exposed rats (Feron et al., 1978). On the other hand, the
BW of male rats exposed to MAwas statistically signiﬁcantly lower
than that of sham-exposed male rats. This effect is most likely
caused by the exposure to high concentrations of nicotine, and was
also observed in a previously published nicotine inhalation study
(Phillips et al., 2015a), as well as in other studies where nicotine
was administered (Chowdhury, 1990; Ijomone et al., 2014; Seoane-
Collazo et al., 2014). It has been shown that nicotine treatment
increases brown adipose tissue thermogenesis and lower blood
glucose levels, leading to an overall negative energy balance
(Seoane-Collazo et al., 2014) which could explain blood glucose
levels and lower BW in THS2.2M groups compared with sham. In
addition, food consumption in THS 2.2M rats was higher than in
sham-exposed rats, supporting this hypothesis.
No differences in BW development were observed in femalerats; that seems to be a typical observation in 90-day smoke
exposure studies (Ayres et al., 2001; Renne et al., 2006).
The respiratory tract is the main target organ system for inha-
lation exposure. Therefore, the most signiﬁcant differences be-
tween MS from MRC and the MA from THS2.2M were expected in
the respiratory tract. Histopathological alterations induced by
smoke from cigarettes are well described (Baker et al., 2004;
Coggins et al., 1980, 1989; Fujimoto et al., 2015; Kogel et al., 2014;
Roemer et al., 2004; Schramke et al., 2014; Terpstra et al., 2003;
Vanscheeuwijck et al., 2002), and similar changes have been
observed with MS exposure in the present study. The alterations
caused by the MA of THS2.2M in respiratory tract organs were
much less pronounced than in the rats exposed to MS from all
reference cigarettes, and similar to those observed in rats exposed
to THS2.2 (Wong et al., 2016 (in this issue)). To better understand
the observed changes, nasal epithelium, lung, and BALF were
investigated on the molecular level to complement standard toxi-
cological endpoints.
Rats are obligate nose breathers, and therefore the nasal
epithelia showed the most pronounced responses. Typical smoke-
related phenotypic alterations were observed in the nose of MRC
MS-exposed rats, including hyperplasia or squamous metaplasia of
goblet cells, respiratory epithelium, or olfactory epithelium, cell
atrophy, and degeneration of the glomerular layers in the olfactory
bulb. In linewith the signiﬁcant changes in tissue architecture, gene
expression analysis of the RNE showed that up to 8000 genes and
1300 proteins were differentially altered in MRC MS-exposed rats.
As part of this response, gene set analysis identiﬁed several affected
biological processes that could be linked to the adaptive changes in
the epithelium, such as epithelial cell differentiation, extracellular
structure organization and tissue remodeling, and cell proliferation
and migration processes. In addition, the analysis of epithelial cell
marker panels clearly corroborated the histopathological ﬁndings
on the molecular level (for more details, see accompanying
manuscript by Kogel et al. (2016 (in this issue)). In contrast, in the
THS2.2M MA-exposed rats, the histopathological alterations
described above were present only in the high THS2.2M group at
nose level 1, and absent from the more distal nasal section levels.
This difference was further conﬁrmed on the molecular level, as the
nasal epithelium of THS2.2M-exposed rats showed a much lower
number of genes or proteins with signiﬁcantly differential expres-
sion compared with MRCeexposed rats at the same nicotine con-
centration. More DEGs and DEPs were found in female than in male
rats; this is consistent with the slightly higher severity of the his-
topathological ﬁndings in the female rats. A more detailed
description of the molecular changes associated with the MS/MA
exposure is provided in the accompanying article (Kogel et al., 2016
(in this issue)).
Following the 42-day post-inhalation recovery period, most of
the observed nasal alterations were reversed or reduced, compared
with the end of the inhalation period. One exception to this was the
increase in goblet cell proliferation after a signiﬁcant loss of goblet
cells observed immediately following the 90-day exposure to MRC
MS and THS2.2M High MA. This effect can be considered a positive
physiological response to regenerate the cells which were lost
previously, and is in line with observations previously described
(Hotchkiss et al., 1995).
Changes observed in the larynx in response toMRCMS exposure
consisted mainly of basal cell hyperplasia and squamous meta-
plasia with or without keratosis in the ventral epithelium overlying
the submucosal gland, arytenoids, ventral pouch, and the vocal
folds, with a high incidence and maximum severity scores. In
contrast, a concentration-dependent increase in basal cell hyper-
plasia was noted in THS2.2MMA-exposed rats, with low incidences
and severities only. Unlike histopathological changes in the nose,
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alterations in the larynx are generally particle-driven. The fact that
the histopathological ﬁndings in THS2.2M High-exposed rats were
much less pronounced compared with MRC-exposed rats at the
same TPM concentration indicates that the TPM compositions of
THS2.2M and MRC are signiﬁcantly different, and further supports
our study design, whereby target nicotine concentrations, not TPM,
are the dosing parameter.
Previous studies have shown that the typical changes, such as
cell hyperplasia, result from a local inﬂammatory response (Lam,
1980; Vidic et al., 1974). Exposure to high concentrations of MS as
used in this study resulted in the loss or necrosis of larynx epithelial
cells. Epithelial regeneration was rapid, and followed by develop-
ment of hyperplasia within days. Basal cell hyperplasia and squa-
mous metaplasia can therefore be considered protective during
repeated test atmosphere exposures (Lam, 1980).
In the lung, the morphological alterations of MRC MS-exposed
rats were analogous to those reported in the literature for sub-
chronic MS inhalation studies using reference cigarettes such as
1R4F or 2R4F (Coggins et al., 1980, 1989; Gaworski et al., 1997;
Vanscheeuwijck et al., 2002). These changes include accumula-
tion of macrophages in the alveolar lumen andmacrophage nests in
the alveolar epithelium, all indicative of inﬂammation. In addition
to the reported higher number of free lung cells in the BALF from
MS-exposed rats, cytokines and chemokines that play an important
role in the recruitment and activation of inﬂammatory cells, such as
macrophages, neutrophils, and lymphocytes, were also upregu-
lated. Gene expression and proteomic analysis of the lung tissue
showed that up to 2800 genes and 100 proteins were differentially
expressed in the lung of MRC MS-exposed rats compared with
sham-exposed rats. Analysis of this response at the level of bio-
logical networks, gene sets, and immune cell marker panels clearly
supported the activation of a lung immune response involving
macrophages and neutrophils byMS exposure (Kogel et al., 2016 (in
this issue)). Some highly expressed proteins were identiﬁed,
including S100A8, which forms a heterocomplex with S100A9,
termed S100A8/A9 or calprotectin. Functions of S100A8/A9 in-
cludes pro-inﬂammatory activities (Miyasaki et al., 1993).
In contrast to MS exposure, no MA exposure-related inﬂam-
matory changes were detectable in the lung. Gene and protein
proﬁling conﬁrmed the overall much lower impact of MA on the
molecular level e including the aforementioned immune response
(Kogel et al., 2016 (in this issue))
Finally, the absence of morphologic and inﬂammatory alter-
ations was also in line with a lower relative and absolute lung
weight compared with MS-exposed rats. The absence of changes in
the lung of the rats exposed toTHS2.2M is consistent with what has
been reported for THS2.2 (Wong et al., 2016 (in this issue)).
In contrast to ﬁndings in the respiratory tract organs, systemic
effects of test atmosphere exposure, such as higher activities of the
enzymes alkaline phosphatase, lower cholesterol, triglycerides, and
glucose concentrations, higher numbers of neutrophils in blood,
and changes in the relative weight of certain organs were of the
same magnitude in MRC- and THS2.2M-exposed rats.
These ﬁndings have been reported as MS inhalation ﬁndings
(Boelsterli et al., 1984; Everds et al., 2013; Piade et al., 2014; Terpstra
et al., 2003; Vanscheeuwijck et al., 2002), and considered to be
most likely nicotine- and stress-related (Everds et al., 2013).
However, more recent work has demonstrated that when rats are
exposed to nicotine-containing aerosols, similar changes are
observed (Phillips et al., 2015a), indicating that the mild toxico-
logical changes observed upon THS2.2M exposure are most likely
caused by nicotine.
A second MRC with higher menthol level in MS was included in
the study to match the menthol level in THS2.2M High. Thisprovided the opportunity to investigate menthol-related effects in
MS-exposed rats, analyzing the results from MRC(LM), MRC(HM),
and 3R4F.
Only a few endpoints showed a statistically signiﬁcant effect of
menthol exposure in the MRC(HM) groups compared with 3R4F,
including a lower total BALF cell count, lower number of neutro-
phils and macrophages, higher numbers of erythrocytes in male rat
peripheral blood but lower in female rats, higher hematocrit in
male rats but lower in female rats, and lower relative uterus weight
in female rats. These ﬁndings are, however, not supported by the
limited published data, or are not consistent with other results
obtained in this study.
Gaworski et al. exposed rats to cigarettes spiked with 5000 ppm
menthol in a 13-week nose-only smoke inhalation toxicity study
(Gaworski et al., 1997). Analysis of the MS produced by the
mentholated cigarettes indicated that approximately 2% of the TPM
was menthol, whereas the highest menthol concentration in our
study was about 0.5% in TPM. In another 13-week nose-only smoke
inhalation toxicity study, in which cigarettes were spiked with
18,000 ppm menthol (Vanscheeuwijck et al., 2002), no menthol-
related changes were reported that concerned numbers of eryth-
rocytes and reticulocytes or uterus weight.
Exposure to MRC(HM) led in male rats to lower total BALF cell
counts, as well as lower neutrophil and macrophage numbers
compared with 3R4F, indicating a slightly lower inﬂammatory
response. However, these results are not supported by other study
endpoints, such as cytokine expression in BALF, pathological ﬁnd-
ings in the lung, or differential gene and protein expression in the
lung.
Willis et al. reported that menthol attenuated respiratory irri-
tation responses in mice to multiple cigarette smoke irritants, such
as acrolein and acetic acid, concluding that menthol may facilitate
smoke inhalation (Willis et al., 2011). Likewise, Ha et al., reported
that L-menthol, through Transient Receptor Potential Melastatin 8
(TRPM8), is a strong suppressor of respiratory irritation responses
in smoke-exposed mice, and increases blood cotinine (Ha et al.,
2015). The potential reduction of the irritant by menthol is not
conﬁrmed by the data collected from exposure toMRC as compared
to 3R4F, as there was no difference in the respiratory frequency or
in the levels of COHb, nicotine, or cotinine in blood between 3R4F-
andMRC-exposed groups, regardless of thementhol level in smoke.
Similarly, Gaworski (Gaworski et al., 1997) found similar blood
levels of nicotine and cotinine in rats exposed for 1 h/day for 90
days to smoke from mentholated and nonmentholated cigarettes,
but lower COHb levels in rats exposed to smoke from mentholated
cigarettes.
In conclusion, heating tobacco rather than burning it leads to a
remarkable reduction in toxicologically-relevant constituents in
the produced aerosols and the test atmospheres, resulting in
notable and signiﬁcantly smaller biological effects. As reported in
previous studies for heated tobacco products (Ayres et al., 2001;
Kogel et al., 2014; Roemer et al., 2004; Terpstra et al., 2003;
Werley et al., 2008), exposure to MA from THS2.2M induced
lower BW gain suppression, subdued histopathological changes in
the respiratory tract organs, and decreased pulmonary inﬂamma-
tion compared with MRC MS. Furthermore, gene and protein
expression investigations demonstrated that no new adverse ef-
fects of THS2.2M MA were present. Addition of menthol to heat-
not-burn products results in effects that do not appear to differ
from effects of non-mentholated similar products (Wong et al.,
2016 (in this issue)). Study result meta-analysis may shed some
additional light on the effects of menthol in THS products; for
which, to achieve the best possible outcome for such a comparison,
a single pathologist should read both studies, and in a group
designation-blinded manner.
A. Oviedo et al. / Regulatory Toxicology and Pharmacology 81 (2016) S93eS122 S121In addition, and as evidenced by the similarity of the results
between 3R4F-exposed animals and those exposed to MS from
cigarettes with two added concentrations of menthol, menthol
displays no apparent effects when added to cigarettes.
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